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ADP Arteria dorsalis pedis
AK Above knee
APP Assisted primary patency
ASA Acetylsalicylic acid
ATA Arteria tibialis anterior
ATP Arteria tibialis posterior
Avf Arteriovenous fistula
BK Below knee
CAD Coronary artery disease
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Study
CASPAR Clopidogrel and Acetylsalicylic acid in bypass Surgery for
Peripheral ARterial disease Study
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DUAM Duplex ultrasound arterial mapping
HUV Human umbilical vein
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LMWH Low molecular weight heparin
LS Leg salvage
MFC Maximum flow capacity
MRA Magnetic resonance angiography
NS Not significant, p> 0.05
PAD Peripheral arterial disease
PP Primary patency
PTFE Polytetrafluoroethylene
PVR Pulse volume recording
S Survival
SCanPAC SCandinavian Prothesis, Av-fistula and Cuff Study
SFA Superficial femoral artery
SE Standard error
SLI Symptomatic leg ischaemia
SP Secondary patency
TASC Trans-Atlantic Inter-Society Consensus Document on
Management of Peripheral Arterial Disease
TTV Thrombotic threshold velocity
Vmax Maximum flow velocity




A lack of suitable venous graft material or poor outflow is an increasingly encountered
situation in peripheral vascular surgery. Prosthetic grafts have clearly worse patency than
vein grafts in femorodistal bypass surgery. The use of an adjuvant arteriovenous fistula
(av-fistula) at the distal anastomosis has been postulated to improve the flow and thus
increase prosthetic graft patency. In theory the adjuvant fistula might have the same effect
in a compromised outflow venous bypass. A free flap transfer also augments graft flow and
may have a positive effect on an ischaemic limb.
Aims of the study
The aim of this study was to evaluate the possible benefit of an adjuvant av-fistula and an
internal av-fistula within a free flap transfer on the patency and outcome of an infrapopliteal
bypass. The effect of the av-fistula on bypass haemodynamics was also assessed along
with possible adverse effects.
Patients and methods
1. A prospective randomised multicentre trial comprised 59 patients with critical leg
ischaemia and no suitable veins for grafting. Femorocrural polytetrafluoroethylene (PTFE)
bypasses with a distal vein cuff, with or without an adjuvant av-fistula, were performed.
The outcome was assessed according to graft patency and leg salvage.
2. Haemodynamic measurements were performed to a total of 50 patients from Study I
with a prolonged follow-up.
3. Nine critically ischaemic limbs were treated with a modified radial forearm flap transfer
in combination with a femorodistal bypass operation. An internal av-fistula was created
within the free flap transfer to increase flap artery and bypass graft flow.
4. The effect of a previous free flap transfer on bypass haemodynamics was studied in a
case report.
5. In a retrospective multicentre case-control study, 77 infrapopliteal vein bypasses with an
adjuvant av-fistula were compared with matched controls without a fistula. The outcome
and haemodynamics of the bypasses were recorded.
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Main results
1. The groups with and without the av-fistula did not differ as regards prosthetic graft
patency or leg salvage.
2. The intra- and postoperative prosthetic graft flow was significantly increased in the
patients with the av-fistula. However, this increase did not improve patency. There was no
difference in patency between the groups, even in the extended follow-up.
3. The vein graft flow increased significantly after the anastomosis of the radial forearm
flap with an internal av-fistula.
4. A previously performed free flap transfer significantly augmented the flow of a poor
outflow femoropedal bypass graft.
5. The adjuvant av-fistula increased the venous infrapopliteal bypass flow significantly. The
increased flow did not, however, lead to improved graft patency or leg salvage.
Conclusion
1. An adjuvant av-fistula does not improve the patency of a femorocrural PTFE bypass
with a distal vein cuff.
2. The av-fistula increased the flow values, both in the intraoperative measurements and
during the immediate postoperative surveillance. The increased flow values nevertheless
did not improve patency. The adjuvant av-fistula did not cause any adverse effects.
3. In a group of diabetic patients, the flow in a vascular bypass graft was augmented by an
internal av-fistula within a radial forearm flap.
4. In a patient with a previous free flap transfer, a high intraoperative graft flow was
achieved due to the free flap shunt effect.
5. The adjuvant av-fistula increased graft flow significantly in a poor outflow venous
bypass, but this effect did not result in clinical benefit.
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5. INTRODUCTION
Atherosclerosis is a systemic disease. Disturbances in the balance between blood, flow
and the arterial wall lead to thrombus formation in low flow states to the diseased arterial
wall. The occlusive lesions caused by atherosclerosis with superimposed thrombosis in the
arteries of the lower extremities lead to the symptoms of chronic leg ischaemia and the
entity called peripheral arterial disease (PAD). Reduced blood flow to the extremity causes
claudication or, in a more critical stage, rest pain or tissue loss, thus threatening the
viability of the limb. This latter entity is called chronic critical leg ischaemia (CLI). The
incidence of CLI varies according to different estimations between 500-1000/million/year
(Norgren et al. 2007).
The manifestations of ischaemia were first defined into the four categories by Fontaine’s
classification (Fontaine et al. 1955). Asymptomatic disease (class I) or claudication (class
II) seldom leads to limb loss (Dormandy et al. 1991), whereas patients with rest pain (class
III) and those with ulcer or gangrene (class IV) are at risk of losing their limb. The main
objective of vascular procedures is to prevent limb loss and sustain the patient’s
ambulatory status and quality of life.
Along with bypass surgery, endovascular procedures offer an alternative. The
revascularization policy is shifting from traditional bypass surgery towards endovascular
procedures both in primary and secondary procedures (Nasr et al. 2002, Kudo et al. 2004).
According to the latest TASC II recommendations (Norgren et al. 2007), bypass surgery is
still the golden standard for long multisegmental lesions. In a randomised study, bypass
and angioplasty in critical ischaemia were compared, and it was concluded that due to the
high failure and re-intervention rate of endovascular procedures, bypass surgery provides
a more durable result than angioplasty (Adam et al. 2005). Thus, despite the constantly
developing endovascular techniques, there are still patients with extensive infrainguinal
disease and critical ischaemia beyond the endovascular therapy options.
The mean age of the patients, as well as the prevalence of diabetes is increasing
(Onkamo et al. 1999). The progression of the atherosclerotic disease and graft failure
result in recurrence of critical ischaemia in an elderly patient population with numerous co-
morbidities and previous vascular procedures. In this patient population the graft material
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is often sparse and the outflow tract limited. Co-morbidities present a challenge because
they increase postoperative morbidity and the risk of mortality. The extensive ulcers with
tissue necrosis and infection in diabetic patients may require a vascularised free tissue
transfer in addition to a bypass to achieve wound healing (Tukiainen et al. 2006). In a
situation where the bypass graft is poor, the outflow limited, and tissue loss is extensive,
the feasibility of the bypass operation can be questioned. However, an aggressive policy in
vascular surgery, especially infrainguinal reconstructions, has been shown to reduce
amputation rates (Eskelinen et al. 2004, Winell et al. 2006) and to be cost-effective in
terms of salvaged limbs and sustained ambulatory status of the patient (Luther 1997a).
Saphenous vein bypass is the gold standard of infrainguinal bypass surgery. In patients
with critical ischaemia, the best long-term results in both bypass patency and leg salvage
are achieved with autologous vein bypass (Veith et al. 1986, Shah et al. 1995b). Even
alternative sources of autologous vein perform better than prosthetic grafts (Faries et al.
2000, Chew et al. 2001, Curi et al. 2002).
Infrapopliteal prosthetic bypass may be an alternative to primary amputation to ensure limb
salvage in patients with critical leg ischaemia and no suitable autologous conduits. The
patency of a prosthetic bypass is inferior to that of a venous bypass (Veith et al. 1986,
Sayers et al. 1998) and therefore adjunctive methods to improve patency and outcome
have been developed. Vein cuff interposition was introduced to facilitate the anastomosis
between the non-compliant graft and a native artery (Miller et al. 1984, Tyrrel & Wolfe
1991). The true mechanism behind the protective effect of the vein cuff is unclear, but it is
thought that the vein cuff reduces the mismatch in compliance between the recipient artery
and the prosthetic graft. The venous endothelium may also have a beneficial effect against
the formation of myointimal hyperplasia (Norberto et al. 1995). Hyperplasia accumulates in
areas of low shear stress in an anastomosis. It has been shown in an experimental model
that the vein cuff alters the flow, which results in the shifting of sites of low shear stress
away from critical sites of the anastomosis (How et al. 2000).
Prosthetic materials are highly thrombogenic, and thus low flow in a poor run-off graft
further increases the risk of thrombosis. Sauvage first hypothesised thrombotic threshold
velocity, i.e. a velocity below which thrombosis occurs (Sauvage et al. 1979). An adjuvant
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av-fistula ideally increases the flow velocity above the thrombotic threshold, increases
shear stress, and counteracts vessel shrinkage and stenosis.
Most diabetic wounds are neuropathic. Neuropathy may cause a lesion, which is often
complicated by infection, and healing is prevented by inadequate tissue perfusion caused
by ischaemia (Oyibo et al. 2002, Heikkinen et al. 2007). Radical wound excisions and skin
grafting are seldom sufficient to achieve ulcer healing. A vascularised free flap transfer in
combination with an infrainguinal reconstruction may therefore be indicated to prevent
major amputation (Tukiainen et al. 2000, Vermassen et al. 2000, Illig et al. 2001).
Diabetic vascular disease was proposed to cause microangiopathy and affect the small
arteries of the foot. This view has nevertheless been contradicted by numerous studies
focusing on the pattern of PAD in diabetics. The tibial vessels are often affected in the leg,
whereas the arteries of the foot are less frequently involved (LoGerfo & Coffman 1984,
Diehm et al. 2006). An angiographic study of run off showed that the small arteries of the
foot in both diabetics and non-diabetics were similarly affected (Karacagil et al. 1989b).
The dorsal pedal artery is often spared to allow a bypass (Andros 2004) and with crural
vessel involvement, bypasses from the popliteal level to pedal arteries can be performed
to achieve leg salvage (Shah et al. 1995a, Biancari et al. 2000a).
A bypass to a foot artery often offers a limited run off. A free flap transfer in combination
with a vascular bypass procedure significantly increases the outflow bed and consequently
bypass graft flow (Lorenzetti et al. 2001). Therefore, in these patients a free flap transfer
can be used with two aims: as tissue coverage and as an aid to maintain bypass graft
patency.
Outflow is one of the strongest determinants of bypass outcome in infrainguinal bypass
surgery (Albäck et al. 1998, Seeger et al. 1999). In patients with critical ischaemia, the
outflow is often compromised, and even worse in redo surgery. The status of the outflow
artery may be worse than anticipated, or the flow achieved by the bypass may indicate a
high-risk graft. There may also be situations in which the extremity requires a free flap in
adjunction with a bypass graft to cover the ischaemic tissue loss. Some encouraging
reports have been published on a prosthetic bypass and av-fistula (Dardik et al. 1991,
Harris et al. 1993, Biancari et al. 2001). Because low graft flow predicts also infrainguinal
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vein graft failure (Albäck et al. 2000), the rationale to create an adjuvant av-fistula was that
it might be beneficial not only in a prosthetic bypass, but also in a venous bypass. An
internal av-fistula was created within a radial forearm free flap transfer with the intention to
increase flap flow and thus possibly also bypass graft flow. The haemodynamic changes
caused by a patient’s previous free flap transfer were evaluated.
This study has been carried out mostly among an aged patient population with critical leg
ischaemia and numerous co-morbidities. These patients were presented with suboptimal
bypass grafts and a poor outflow bed. The aim of the study was to assess the possible
benefit of an adjunctive av-fistula on both prosthetic and venous bypass graft patency, to
assess possible adverse effects that the av-fistula may cause, to assess the effects of a
previously reconstructed free flap on graft flow, and to present a novel method of free flap
transfer with an internal av-fistula.
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6. REVIEW OF THE LITERATURE
6.1 VEIN GRAFT BYPASS
6.1.1 The saphenous vein bypass
The saphenous vein is the conduit of choice for infrapopliteal bypass. Infrapopliteal bypass
is mainly performed for limb salvage, and therefore the long-term performance of the graft
is essential (Rafferty et al. 1987, Leather et al. 1988, Belkin et al. 1996). In a large patient
series studied by Shah et al. (1995b) more than 2000 patients were followed for over 10
years, giving a secondary patency rate of 91%, 81% and 70% respectively, at one, five
and 10 years. The limb salvage rate was 97%, 95% and 90% during the same period. 91%
of the patients in the study had critical leg ischaemia and 67% had Fontaine IV lesions,
indicating that surgery was mainly performed to achieve limb salvage.
The excellent performance of the saphenous vein graft has also been seen in the reports
of Veith et al. (1986) and Sayers et al. (1998). Compared to a prosthetic popliteal,
infrapopliteal and femorotibial bypass, the vein bypass performed far better and gave
better results in the long run. At four years the primary patency of infrapopliteal vein
bypass was 49% compared to 12% of PTFE grafts in the report by Veith and coworkers
(1986). In a study by Rafferty et al. (1987) the three-year patency was 43% for femorotibial
vein bypasses and 19% for prosthetic bypasses. In Sayers’s study (1998) the primary
patency was 54% at two years of vein grafts, compared to 31% of PTFE grafts. These
studies concluded that femorotibial bypass provided good long-term results, and that
saphenous vein graft is the optimal choice for these bypasses.
The saphenous vein can be used both in situ and as a reversed vein. It was proposed that
the in situ technique would yield better patency, because the graft is manipulated less and
the vasculature thus remains untouched, and possibly the endothelium better preserved.
Bush and coworkers (1983) suggested that increased operative blood flow and
postoperative patency were achieved by the in situ technique. In an endovascular in situ
bypass series of Rosenthal et al. (1994) additional benefits were achieved by the
endovascular technique in the form of reduced hospital stay, fewer wound-related
complications and shorter recovery. In a large series investigated by Taylor et al. (1990),
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however, 516 reversed vein bypasses were reported to have equal patency when
compared with the in situ technique, i.e. secondary patency above 76% at five years. In a
number of other large series with both reversed and in situ saphenous vein grafts, there
was no difference between the groups, irrespective of the method used (Londrey et al.
1991, Morris et al. 1993, VA Group 1988). Finally, in two randomised series studied by
Wengerter et al. (1991) and Harris et al. (1993) the in situ vein bypass was compared to a
reversed vein infrapopliteal bypass. Equal patency rates were achieved by both methods;
therefore, currently it is generally accepted that the saphenous vein is the optimal graft,
regardless of whether it is used in situ or reversed.
6.1.2 Alternative vein bypass
Wengerter et al. (1991) noted that in their series, 30% of the patients requiring
infrapopliteal bypass had no suitable vein for the in situ technique. Alternative sources of
graft material were thus often searched. In the absence of the ipsilateral saphenous vein,
the question arises which vein to use as the primary alternative. Some believe that the
contralateral saphenous vein should be saved for the subsequent revascularization of the
contralateral leg or for coronary artery bypass surgery, while others emphasize minimizing
operative injury to the revascularized leg, and prefer to use the contralateral saphenous
vein (Chew et al. 2002). Nevertheless, long enough segments of arm vein can also be
harvested to allow crural bypass.
Holzenbein et al. (1996) reported a series of 250 arm vein bypasses to infrapopliteal
arteries. They achieved a three-year patency of 52% and a leg salvage rate of 92%. The
authors concluded that the arm veins were easily accessed and vein configuration or
splicing did not affect patency rates, but that the vein quality should first be confirmed by
angioscopy. Results on 520 arm vein bypasses were reported by Faries et al. (2000),
yielding a five-year patency rate of 58% and leg salvage of 72%. Single-segment and
spliced veins resulted in equal patency and, on the whole, the long-term performance of
the arm vein bypass was superior to that reported for prosthetic or cryopreserved grafts.
All autogenous graft material can be used in almost all instances if graft material is actively
searched, as proposed by Kent et al. (1989). Chew et al. (2001) reported a series of 165
autogenous composite vein bypasses with a five-year secondary patency of 65% and leg
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salvage of 81%. Good long-term results could thus be achieved, but spliced vein grafts
required surveillance and revision more often than one-segment grafts (Gentile et al. 1996,
Chew et al. 2001).
Curi and coworkers (2002) compared an autogenous spliced vein graft to a single-
segment saphenous vein graft, as well as to a prosthetic graft. In the infrapopliteal position
the autogenous spliced graft performed equally well in the long run as the saphenous vein
graft, and was far superior to the prosthetic conduit.
Gentile et al. (1996) reported a large retrospective series of 919 patients with ipsilateral or
contralateral saphenous vein or alternative autogenous vein bypass. The alternative vein
bypass required revision more often, but still the five-year patency and leg salvage rate
with an alternative autogenous vein was similar to that of a single-segment saphenous
vein bypass.
The lesser saphenous vein is also relatively easily harvested, but often requires splicing
due to its inadequate length (Weaver et al. 1987, Shandall et al. 1987). It is claimed to be
easier to handle than arm veins, which tend to be thin-walled. Problems in wound healing
sometimes occur, because in distal bypasses skin flaps result from harvesting the lesser
saphenous vein. Suction drains and exposition with the aid of duplex mapping has been
suggested to overcome these problems (Chang et al. 1992).
Schulman and coworkers (1987) first introduced deep veins as arterial grafts in a
randomised study. Femoral-popliteal veins performed equally well as saphenous vein
grafts in this study of femoropopliteal bypasses. Venous morbidity has been shown to be
minimal despite the deep vein harvest in later series of superficial femoral vein grafts
(Wells et al. 1999, Modrall et al. 2004).
6.1.3 Outflow level
Good long-term patency and leg salvage has been achieved in a series of vein bypasses
to crural arteries. Even bypasses to a single artery outflow have yielded acceptable
results. A number of patients have stenosis or occlusions in the superficial femoral artery
and popliteal artery, and therefore the crural arteries offer the most proximal site for the
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distal anastomosis. Ideally a bypass should be done to the first artery in continuity with the
pedal arch (LoGerfo & Gibbons 1996, Andros 2004). (Table I)
Excellent results are reported also with pedal artery bypass. Pomposelli and his coworkers
(2003) published a series of 1000 patients with pedal artery bypass and long-term follow-
up. Even emergency pedal artery bypass has been reported; in cases of acute
thromboembolism or ischaemia a pedal artery bypass was attempted without preoperative
angiographic imaging to achieve foot salvage (Hofmann et al. 2003). (Table II)
Bypasses to plantar and tarsal artery branches with a vein graft have also been reported.
In these series the patients have had either previous pedal artery bypass, or no visible
pedal artery in preoperative angiography. Acceptable leg salvage rates have been
achieved even in these series. (Table III)
According to the literature a vein graft, both a single-segment and a spliced vein graft,
performs well in a distal outflow site and in a compromised outflow bed. However,
contradictory reports exist as well. Poor outflow and especially an occluded pedal arch
predicted poor patency of femorodistal and pedal bypasses in the studies of Karacagil et
al.(1990) and Albäck et al. (2000).
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Table I
Outcome after crural artery bypasses with vein grafts
PP PP PP PP PP SP SP SP SP SP LS LS LS LS LS S S S S SAuthor No.ofbypasses 1-year 2-year 3-year 4-year 5-year 1-year 2-year 3-year 4-year 5-year 1-year 2-year 3-year 4-year 5-year 1-year 2-year 3-year 4-year 5-year
Bergamini et al 1991 246 75 66 63 - - 89 86 85 - - - - - - - - - - - -
Hickey et al 1991 239 - - - - - 84 - 83 - 82 - - - - - 81 - 62 - 60
Anderson et al 1992 * 228 - - - - - 62-82 - 60-79 - - 78-90 - 74-85 - - - - - - -
Cheshire et al 1992 89 - - 54 - - - - 72 - - - - - - - - - - - -
Schneider et al 1993 203 - - 61 - - - - 79 - - - - 87 - - - - 64 - -
Darling et al 1995 732 84 - 75 - 70 89 - 83 - 78 96 - - - 93 - - - - -
Shah et al 1995b ** 1271 77-85 - - - 66-78 86-95 - - - 76-86 97 - - - 94 86 - - - 51
Eslami et al 1997 130 - - - - 50 - - - - 70 - - - - 79 - - - - 55
Luther&Lepäntalo 1997 209 57 - 53 - 47 69 - 66 - 53 81 - 76 - 71 - - - - -
Sayers et al 1998 *** 251 63 54 - - - 66 56 - - - 81 73 - - - 84 74 - - -
vanDamme et al 2003 90 - - - 80 - - - - 86 - - - - 88 - - - - 54 -
Outcome endpoints are reported in percentages
PP= primary patency, SP= secondary patency, LS= leg salvage, S= survival
*   divided into groups according to crural outflow artery
**  divided into groups according to outflow artery, in leg salvage and survival pedal bypasses also included
*** in leg salvage and survival, prosthetic bypasses also included
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Table II
Outcome after pedal artery bypasses
PP PP PP PP PP SP SP SP SP SP LS LS LS LS LS S S S S SAuthor No.ofbypasses 1-year 2-year 3-year 5-year 10-year 1-year 2-year 3-year 5-year 10-year 1-year 2-year 3-year 5-year 10-year 1-year 2-year 3-year 5-year 10-year
Davidson&Callis 1993 43 89 - 79 - - 92 - 82 - - 94 - 86 - - - - - - -
Schneider et al 1993 53 - - 58 - - - - 82 - - - - 92 - - - - 61 - -
Tordoir et al 1993* 30 67 - 55 - - 75 - 64 - - - - 82 - - - - - - -
Bergamini et al 1994 99 74 70 70 - - 77 77 77 - - 83 83 - - - - - - - -
Gloviczki et al 1994 100 67 - 60 - - 78 - 69 - - 85 - 79 - - 90 - 83 - -
Isaksson&Lundgren
1994 33 76 - - - - 89 - - - - 89 - - - - 82 - - - -
Darling et al 1995 238 82 - 71 57 - 86 - 78 67 - 94 - - 86 - - - - - -
Robison et al 1995 111 - - - 57 - - - - 61 - - - - 64 - - - - - -
Shah et al 1995b 152 82 - - 68 - 92 - - 77 - - - - - - - - - - -
Abou-Zamzam et al
1996 46 63 - 49 - - - - - - - 70 - 70 - - 84 - 69 - -
Eckstein et al 1996 56 65 55 - - - 71 62 - - - 77 71 - - - 89 78 - - -
Luther&Lepäntalo
1997a 109 - - - - - 59 59 59 - - - 60 60 - - 80 69 54 - -
Biancari et al 1999 ** 162 43 - 34 - - 50 - 41 - - 66 - 60 - - 76 - 55 - -
Dorweiler et al 2002 49 - - - 89*** - - - - - - - - - 87*** - - - - - -
Frankini& Pezzella 2003 43 - - - - - 58 - 39 - - 56 - 46 - - - - - - -
Pomposelli et al 2003 1032 - - - 57 38 - - - 63 42 - - - 78 58 - - - 49 24
Staffa et al 2005 54 - - - 76 **** - - - - 78 **** - 81**** - - - - - -
Outcome endpoints are reported in percentages
PP= primary patency, SP= secondary patency, LS= leg salvage, S= survival
*30 pedal bypasses in a series of 141, patency calculated for the whole group, leg salvage for pedal bypasses only
** 20 patients with PTFE or combined bypass included
*** patency and leg salvage at four years
**** patency and leg salvage at 54 months
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Table III
Outcome after plantar artery bypasses
PP PP PP PP SP SP SP SP LS LS LS LS S S S SAuthor No.ofbypasses 1-year 2-year 3-year 5-year 1-year 2-year 3-year 5-year 1-year 2-year 3-year 5-year 1-year 2-year 3-year 5-year
Ascer et al 1988 20 89 81 - - - - - - 85 85 - - - - - -
Andros et al 1989 20 (24) 73* - - - - - - - 89 - - - 81 - - -
Quinones-Baldrich et al 1993 24 (46)** - 72 - - - - - - - 89 - - - - - -
Gloviczki et al 1994 34 (100)*** 67 - 60 - 78 - 69 - 85 - 79 - 90 - 83 -
Luther&Lepäntalo 1997a 20 (109)*** - - - - 59 59 59 - - 60 - - 80 69 54 -
Roddy et al 2001 18 74 - - - - - - - 74 - - - - - - -
Friedman et al 2002 22 - 72 - - - - - - - 82 - - - - - -
Connors et al 2003 24 - 70 - - - - - - - 78 - - - - - -
Frankini&Pezzella 2003 20 (43)*** - - - - 58 - 39 - 56 - 46 - - - - -
Aulivola&Pomposelli 2004 124 67 - - 41 70 - - 50 75 - - 69 - - - -
Hughes et al 2004 98 67 - - 41 70 - - 50 75 - - 69 91 - - 63
Outcome endpoints are reported in percentages
- numbers in brackets are the total number of bypasses in the series
PP= primary patency, SP= secondary patency, LS= leg salvage, S= survival
* SE exceeds 10%
** Life Table data for the whole series, but there were no differences between the subgroup analysis
*** Life Table data for the whole series, pedal bypasses included
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6.2 PROSTHETIC BYPASS
Prosthetic grafts are widely used in bypasses performed for symptomatic leg ischaemia.
They perform acceptably well in the above-knee (AK) position, when used in claudication
patients with good run-off (Rosenthal et al. 1990, Ballotta et al. 2003). Dacron,
polytetrafluoroethylene (PTFE) or human umbilical vein (HUV) grafts are available as
prosthetic material, and the grafts come with standard or special coatings. Graft coatings
are under active research by the graft industry. One of the latest developments is the
heparin-bonded prosthetic graft claimed to have superior patency, i.e. close to the patency
rates achieved by vein grafts (Peeters et al. 2006). However, there is lack of evidence to
support the superiority of one over the other.
Results comparable to those with vein grafts have been achieved in patients with good
run-off. Some authors therefore suggest that the saphenous vein should be saved for later
use, because in most vascular patients the disease progresses and requires repeated
surgery (Prendville et al. 1990, Rosen et al. 1986, Patterson et al. 1990, Quinones-
Baldrich et al. 1992). Two randomised studies were published in 2000 describing the
performance of AK prosthetic bypass. Burger et al. (2000) reported the PTFE graft to have
acceptable short-term patency, and therefore it would be a reasonable alternative in the
AK position. Johnson et al. (2000) reported the initial performance of the prosthetic grafts
to be similar to vein grafts, but during long-term follow-up, it became clear that the vein
bypasses fared better even in the AK position.
The performance of different grafts in the AK position has been tested. In a randomised
trial, no difference was found between Dacron and PTFE grafts in the AK position (Post et
al. 2001). In a multicentre trial, HUV and PTFE were compared in a femoropopliteal
bypass yielding equal patency (McCollum et al. 1991). A Scandinavian multicentre study
showed that polyester grafts fared at least as well as PTFE at two-year follow-up (Jensen
et al. 2007).
It has been estimated that 30% of patients with critical ischaemia have no suitable
saphenous vein to allow autogenous graft bypass. In addition, half of the patients with
secondary procedures have no autogenous graft material available (Belkin et al. 1995,
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Rossi et al. 2003). In the early 1990s prosthetic grafts were used more liberally than
currently, because in the earlier reports prosthetic grafts seemed to perform well. After
long-term follow-up, however, it has become evident that autogenous graft material fares
better in the long run.
The reason for using prosthetic grafts is that in critically ischaemic patients there is no
autogenous graft material to be used. The Veterans Administration Cooperation Study
Group (1989) compared PTFE, umbilical vein and vein bypass in 596 patients who had a
below-knee (BK) or crural bypass. Two-year patency was 76% for a vein bypass and 64%
for a prosthetic bypass in BK position, and 73% and 30% for tibial/peroneal bypasses,
respectively. In a study by Eickhoff et al. (1987) the performance of HUV grafts was found
to be superior to that of PTFE grafts in the below-knee position. Dardik and coworkers
(2002) presented a large series of HUV bypasses from comparative decades. The HUV
graft was reported to offer an alternative when the autologous vein is not available, giving
acceptable long-term outcome even in the crural position. In most of the studies, the
prosthetic bypass to crural arteries is associated with worse patency than the autologous
bypass, and therefore prosthetic bypass is justified only to avoid amputation (Wolfe
&Tyrrell 1991, Jacobsen et al. 1998, Feinberg et al. 1990, Londrey et al. 1991, Schweiger
et al. 1993, Parsons et al. 1996). (Table IV)
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Table IV
Outcome after prosthetic crural bypasses





1-year 2-year 3-year 5-year 8-year 1-year 2-year 3-year 5-year 8-year 1-year 2-year 3-year 5-year
Flinn et al 1988 75 97/3 Crural PTFE - 45 37* - - - - - - - - 75 - -
BK 50 PTFE or - 64 - - - - - - - - - 85 - -
VA study 1988 135 90/10
Crural 50 HUV - 30 - - - - - - - - - 58 - -
87 Crural PTFE or 35 30 - - - - - - - - 62 - - -
Feinberg et al 1990
21
97/3
HUV** 12 6 - - - - - - - - 33 - - -
45 Crural Comp - - - - - 55 49 44 28 - - - - 82
Londrey et al 1991
33
92/8
PTFE*** - - - - - 63 38 26 7 - - - - -
AK 68 PTFE - - - 63 - - - - 72 - - - -
BK 23 PTFE - - - - 38 - - - - - - - - -
Quinones-Baldrich
et al 1992 322 59/41
Crural 9 PTFE - - 22 - - - - - - - - 37 -
AK 12 HUV - - - - - - - - - - - - - -
BK 37 HUV - - - - - 83 77 72 65 - - 73Dardik et al 1993 167 91/9
Crural 51 HUV - - - - - 77 70 58 45 - - - - 56
Morris et al 1993 201 96/4 Crural PTFE - - 21 - - - - - - - 74 - 64 -
Schweiger et al
1993 211 100/0 Crural PTFE 51 46 37 27 - 63 60 45 34 - - 63 - 51
Parsons et al 1996 66 100/0 Crural PTFE 71 47 35 28 - 78 61 55 43 - 84 71 71 66
BK 20 PTFE 63 50 - - - 63 53 - - - 80 75 - -Jakobsen et al
1998 40 100/0 Crural 80 PTFE**** - - - - - - - - - - - - - -
AK 12 HUV - - - - - - - - - - - - - -
BK 29 HUV - - - - - 90 85 81 71 - - - - 80Dardik et al 2002 283 90/10
Crural 59 HUV***** - - - - - 83 75 66 56 - - - - 65
Outcome endpoints are reported in percentages
CLI= critical leg ischaemia, SLI= symptomatic leg ischaemia, AK=above knee, BK=below knee, HUV=human umbilical vein graft
PP= primary patency, SP= secondary patency, LS= leg salvage
* Primary patency at four years
** PTFE-composite or HUV-composite bypass
***Composite or PTFE bypass
****Crural PTFE bypass with distal vein cuff or av-fistula
***** Crural HUV bypass with adjuvant av-fistula
25
6.3 FACTORS AFFECTING BYPASS OUTCOME
A number of factors affect the outcome of a bypass graft. The causes of graft occlusion
can be divided into immediate, early and late causes. Immediate graft failure is often
caused by poor patient selection. Technical error and thrombogenity of the graft material
are the other causes of immediate graft failure. Early graft failure is caused by a technical
error, intimal hyperplasia or blood rheology, and late graft failure by intimal hyperplasia,
bypass deterioration or progression of the atherosclerotic disease. Blood coagulation and
thrombocyte aggregation can be affected by adjunctive medication. Treatment of
concomitant diseases and risk factors prevents the complications caused by the diseases,
and consequently the progression of the atherosclerotic disease (Burns et al. 2003,
Chobanian et al. 2003, Critchley & Capewell 2003, Baigent et al. 2005, Dormandy et al.
2005).
6.3.1 Graft-related causes
The graft material has an important role on the outcome. In a study by Rutherford et al.
(1988) the material of the bypass graft was found to be the most important predictor of
long-term outcome, its influence being the greater, the more distal the bypass was. In
studies with comparative cohorts, prosthetic graft material predicted poor prognosis in the
series studied by Londrey et al. (1991) and Tordoir et al. (1993). Carsten et al. (1998)
suggested that a prosthetic graft should not be used in crural bypasses due to the poor
outcome of these grafts.
Albäck and coworkers (1998) studied the immediate failure of femoropopliteal saphenous
vein grafts and found that almost half of the immediate occlusions were graft-related and
almost as many were due to technical causes. They concluded that a number of
occlusions could be avoided if these matters were carefully addressed. A study by
Donaldson et al. (1992) showed that in 63% of primary saphenous vein graft bypasses,
failure was caused by the graft itself. In the rest of the cases, compromised inflow, outflow
and hypercoagulability were the causes of failure. Panayitopoulos et al. (1997) studied
factors predicting failure of a femorodistal bypass graft and found graft material and
outflow status to be strongest predictors of outcome. In a series of Varty et al. (1993) the
only independent risk factor for immediate vein graft failure was peripheral resistance, but
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a poor quality vein was found to be a risk factor for subsequent graft stenosis. In a study
by Ihlberg et al. (2001) low graft flow was found to predict the development of de novo
stenosis in a vein graft.
In conclusion, the bypass graft itself, whether prosthetic or vein, is a significant factor in
the outcome of infrainguinal bypass surgery. With careful patient and graft selection and
graft monitoring, i.e. intraoperative graft quality control and postoperative surveillance, a
considerable number of occlusions can be avoided (Harward et al. 1994, Idu et al. 2005).
6.3.2 Co-morbidities
Vascular patients typically have a number of co-morbidities. These often determine the
fate of the patient regardless of the fate of the bypass graft. Severe coronary artery
disease, previous stroke, long-term dialysis and diabetes with co-existing infection were
found to be risk factors for both limb loss and mortality in a study by Biancari et al.
(2000b). An increased level of postoperative c-reactive protein (CRP) was predictive of
amputation in a study by Mätzke et al. (2001), possibly indicating an inflammatory state in
these patients. Patients with ulcer and gangrene had higher CRP values, as did patients
with subsequent amputation.
Patients in long-term dialysis and those with coronary artery disease have a poor outcome
according to survival, even if the bypass surgery is successful. Biancari and coworkers
(2002) and Peltonen et al. (1998) concluded that revascularization should not be
attempted in patients on dialysis due to the poor survival and high amputation rate of these
patients. When several risk factors are present, the fate of the patient is poor. Biancari and
coworkers (2007) introduced a risk score for patients with critical limb ischaemia. Diabetes,
coronary artery disease, foot gangrene and urgent operation were each assigned one
point, and a risk score was thus determined. This risk score can be used to predict
postoperative outcome, for example with a high risk score of four, the 30-day
mortality/amputation rate was 22.2%.
Diabetes is present in about half of the vascular patients who require bypass surgery. In a
series where diabetics were compared to non-diabetics in terms of patency and outcome,
no significant difference was found between the groups, except for survival (Wolfle et al.
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2003). In a study by Luther and Lepäntalo (1997b) diabetes and female gender were
prognostic of poor outcome as to patency and limb salvage. In a series of patients with
popliteal-to-distal bypasses, Biancari et al. (2000a) found that diabetes had no effect on
patency, but that survival and amputation-free survival rates of diabetics were significantly
inferior. Carsten et al. (1998) described a series of patients who had limb loss despite a
patent graft. In their patient material, persistent diabetic infection was the cause of early
limb loss, and chronic ulcer and osteomyelitis were the causes of late limb loss. Diabetes
was found to be predictive of amputation also in a study by Seeger et al. (1999), due to
poor wound healing.
Virkkunen and coworkers (2004) studied diabetes as a risk factor for postoperative
complications. There were more Fontaine IV lesions and more distal bypasses in the
group of diabetics, and diabetes was found to be a risk factor for early BK amputation but
not for mortality. Urgency of operation was a significant predictor of adverse outcome in
diabetics. The same was noted by Biancari and coworkers (2007). An urgent operation
may be connected to the concurrent severe infection in a diabetic patient, the infection
itself being a predictor of poor outcome (Mätzke et al. 2001).
6.3.3 Outflow
6.3.3.1 Assessment of outflow
Perhaps the most important predictive factor of bypass graft outcome is the outflow status,
a factor that cannot be controlled. The status is sometimes so poor that the overall
possibility of the reconstruction can be questioned. The predictive role of the outflow has
been addressed in a number of studies. In series where bypass graft failure has been
studied, poor outflow is often one of the main causes of failure (Donaldson et al. 1992,
Panayitopoulos et al. 1997, Varty et al. 1993).
Ways of describing the outflow have been searched to determine a uniform scoring system
to aid in decision-making when a distal bypass is planned. The run-off has been assessed
from the angiographic images by grading the outflow. In the traditional classification, the
run-off was graded from excellent to poor, depending on the status of the popliteal artery
and its tributaries (Linton & Darling 1962). A classification based on three risk groups has
28
been used subsequently, presenting a status of isolated popliteal outflow, one-vessel
outflow, or two- to three-vessel outflow (Miller et al. 1990). In a study by Prendville et al.
(1990) with femoropopliteal prosthetic grafts, patients with poor run-off (0-1 patent crural
vessel) had a significantly worse outcome compared to patients with better run-off. In a
series by Schweiger et al. (1993) the number of patent crural vessels and the patency of
the plantar arch predicted the patency of a prosthetic graft.
6.3.3.2 Run-off score
The run-off score is a scoring system that grades the outflow based on angiographic
findings and the planned site of the distal anastomosis. The guidelines determing the run-
off score were first published by the Ad Hoc Committee in 1986 and the revised version in
1997 (Rutherford et al. 1986 and 1997). Depending on the status of the outflow arteries,
the run-off receives a value from one to ten, one indicating normal outflow and ten blind
outflow. Unfortunately the validity of the run-off score depends on the quality of the
images, so the accuracy of the score can be questioned. Yet, the run-off score has been
widely used as a descriptive method of the outflow tract and its predictive value has been
tested in a number of studies.
Tordoir et al. (1993) reported a series of 121 patients with an infrainguinal bypass. In their
report the run-off score, determined according to the guidelines of the Ad Hoc Committee,
had no predictive value on graft patency. Prosthetic graft material was the only tested
parameter that predicted poor outcome. Takolander et al. (1995) tested the predictive
value of the run-off score in 53 infrainguinal bypass patients. They found that the run-off
score had no effect on the patency at one year. In a study of peroneal bypasses by Plecha
et al. (1993), the run-off score was not a predictor of the outcome.
The intraoperative determinants of graft failure were studied by Blankensteijn et al. (1995).
A run-off score of more than one, i.e. other than normal run-off, predicted early failure in
their study; on the other hand, no graft with a normal run-off failed. Okadome et al. (1991)
also found the run-off score to be predictive of femoropopliteal bypass outcome with a cut-
off value of 4.5. The run-off score predicted the immediate outcome of a femoropopliteal
graft in a study by Albäck et al. (1998) and the fate of a femorocrural graft in a report by
Biancari et al. (1999a). Seeger et al. (1999) studied the potential predictors of outcome in
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a series of 210 patients, and found the run-off score to be the strongest predictor of
outcome in terms of survival, amputation and graft patency.
Karacagil et al. described their own method of scoring the run-off and found it to be
predictive of patency in both femoropopliteal (1989a) and femorodistal bypass (1990). In
their report, the Ad Hoc scoring method did not predict the outcome. Their revised scoring
method did predict patency also in later reports of femoropopliteal and femorodistal grafts
(Ljungman et al. 2000, Ulus et al. 2001).
It is difficult to compare the reports when the Ad Hoc scoring method is used. Some of the
series are small, some retrospective, and the patients differ according to outflow artery and
bypass graft material. The contradictory findings of these series may be explained by the
fact that legs with the most difficult outflow are excluded from operative therapy, as
demonstrated by the small number of pedal bypasses in all the reports.
6.3.3.3 Other means of defining the outflow
Other means to define the outflow have also been described due to the problems inherent
in angiography. Angiography is an invasive examination with a certain, although low,
complication risk, and sometimes it fails to visualise the outflow tract precisely. Doppler
can be used to demonstrate the patency of pedal vessels not seen in angiography, as
proposed by Pomposelli et al. (1990). In a study by Wilson et al. (1997) Doppler,
angiography and duplex ultrasound were used to assess the outflow, and duplex was
found to be most accurate in the crural area. Newer high frequency colour duplex devices
are especially effective in visualising distal arteries. Extremely calcified vessels may
visualize poorly, but in most cases a more accurate image can be obtained with duplex
imaging than with contrast angiography (Hingorani et al. 2007).
Scott et al. (1989) used a pulse-generated Doppler run-off score and compared it to the
angiographic scores. They found that the pulse-generated Doppler score was more
accurate in the crural area in defining the outflow. When Davies and coworkers (1996)
used the same method, they found that the run-off score was strongly associated with the
outcome of the bypass. A pre-operative hand-held Doppler run-off score was described by
Stewart et al. (2002), and this Doppler score correlated with the outcome.
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Stirnemann et al. (1994) described a method to measure flow during the operation and
found this intraoperative flow to be a predictor of the outcome. A very low flow value and a
prosthetic graft resulted in poor outcome.
Peripheral resistance can be calculated from the graft flow intraoperatively. Ascer et al.
(1987) measured peripheral resistance in femoropopliteal and femorodistal reconstructions
and found the outflow resistance to predict patency and limb salvage. Davies et al. (1993)
reported intraoperative graft resistance and flow to be predictive of early outcome.
Intraoperative flow can be measured by the transit time flowmeter. It was introduced and
validated in clinical practice in 1996 (Albäck et al. 1996, Laustsen et al.1996). High
peripheral resistance and low graft flow predicted adverse graft outcome in a study by
Lundell & Bergqvist (1993). Intraoperative graft flow was found to be a predictor of the
outcome also by Albäck et al. (2000). Poor intraoperative flow predicted subsequent de
novo stenosis of a vein graft in a study by Ihlberg et al. (2001).
A run-off score based on Doppler flow measurement of the graft was introduced by
Scwierz et al. (2003). Currently colour duplex is becoming increasingly popular in the
imaging of the peripheral arterial tree. Duplex ultrasound arterial mapping (DUAM) is a
safe and relatively accurate alternative to contrast angiography (Mazzariol et al. 2000,
Hingorani et al. 2004).
Even though the outflow strongly affects the outcome, bypasses to poor outflow have been
attempted. Series of bypasses to an isolated popliteal segment have been described
(Roddy et al. 2002, Mosimann & Stirnemann 1995). Desai and coworkers (2001) reported
a series of 274 patients in whom the outflow score was 10, i.e. blind outflow in one third of
the patients. Acceptable patency was achieved even with blind outflow, which
nevertheless was a predictor of subsequent limb loss, as shown by the worse limb salvage
in the group with the blind outflow.
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6.3.3.4 When to reconstruct
The question remains, when to reconstruct, and when should the attempt be considered
too risky. The bypass graft may be suboptimal, the patient may have a number of co-
morbidities, and the outflow may be poor. The Second European Consensus Document
(1991) proposed that a 25% amputation-free survival rate achieved by surgery justifies
attempts for limb salvage. Because this rate is close to the one achieved with conservative
treatment, a higher success rate of 75% should be attained to justify bypass surgery
instead of primary amputation according to Robison & Beard (1999). In reports from
national vascular registries, similar rates have been achieved in the treatment of critical leg
ischaemia (The Vascular Surgical Society of Great Britain and Ireland 1995, Tröeng et al.
1994).
The outcome of a patient with unreconstructed CLI is poor; only 46% of these patients are
alive at one year, and 28% are alive with a non-amputated leg (Lepäntalo & Mätzke 1996).
In other studies of conservative treatment at 18-24 months, 54% of the patients have had
an amputation (Jivegård et al. 1995, Klomp et al. 1999). On the other hand, if certain risk
factors are present as described by Biancari et al. (2000b), the patient is prone to both
limb loss and life loss. The failure of infrainguinal surgery leads to a poor outcome,
particularly in patients with immediate graft failure and tissue loss. A limb salvage rate of
34% has been reported in these patients after graft failure (Baldwin et al. 2004).
Critical ischaemia often demands repeated surgery. Luther studied the costs of
reconstruction versus amputation in CLI patients. Despite the need for repeat surgery,
reconstructive surgery was found to be cost-effective in potentially mobile patients who are
likely to regain their independent living status, incurring lower costs than amputation when
calculated on the basis of cost/survival year (Luther 1997a). In a study of outcome and
cost analysis (Panayiotopolous et al. 1997), bypass grafting was found to be cost-effective,
because the costs of revascularisation are low compared to amputation. However, in
patients with severe disease, repeat surgery is needed, thus increasing the costs, and
therefore primary amputation may be justified in some patients. Due to the number of
repeated surgical procedures that these demanding patients require, Goshima et al.
(2004) proposed that traditional reporting standards underestimate the expenses and
efforts to attain limb salvage.
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The outcome of failed bypass is poor. Therefore in a situation with a high failure risk due to
the poor graft or outflow, means to predict or detect graft failure are searched. In a series
of 631 grafts under surveillance for an average of 28 months, 26% developed secondary
failure (Baldwin et al. 2004). On the other hand, when long-term results of vein graft
revision were studied, 30.9% of the revised vein grafts developed additional lesions,
leading the authors to conclude that ongoing surveillance is mandatory (Nguyen et al.
2004).
The true benefit of graft surveillance has been studied in randomised studies. In contrast
to the initial observation by Lundell et al. (1995), Ihlberg et al. found in a randomised trial
(1998) and its extension (1999) that there was no difference in the outcome in the groups
with duplex or conventional graft surveillance. This was also observed in the Vein Graft
Surveillance Randomised Trial (Davies et al. 2005); the graft surveillance programme did
not show any benefit in terms of limb salvage, but it did increase the costs.
6.4 ADJUNCTIVE METHODS FOR BETTER BYPASS PATENCY
In CLI patients, adjunctive methods to improve bypass performance are searched in
suboptimal situations. The poor graft material or outflow entail risk to the bypass.
Adjunctive medication is used to prevent graft thrombosis when a thrombogenic graft is
used or a low-flow graft is at risk. Vein cuffs were introduced to improve prosthetic graft
performance. Means to improve the outflow have been introduced in the form of an
adjunctive av-fistula and free flap transfer.
6.4.1 Medication
The role of anti-platelet or anticoagulation medication on graft patency has been studied,
but only in few randomised controlled trials. In some centres anticoagulation is routinely
used in conjunction with prosthetic bypass to improve graft patency. Flinn et al. (1988)
reported improved results from a prosthetic bypass with the use of warfarin. In a
retrospective series the 4-year patency rate was 37% in a series of 75 patients with few
late complications from the adjunctive medication. In a randomised trial conducted by
Sarac et al. (1998), combination therapy with warfarin and acetylsalicylic acid (ASA)
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improved the outcome of infrainguinal bypasses with high risk for failure, i.e. poor graft,
outflow or redo surgery.
The overview of randomised trials by the Anti-platelet Trialists’ Collaboration (1994)
showed that anti-platelet therapy succeeded in reducing the risk of vascular occlusion
irrespective of the anti-platelet regimen used.
Tangelder et al. (1999) published a review of randomised controlled trials of using ASA
and oral anticoagulants. A meta-analysis showed that the absolute risk of graft occlusion
was reduced by 8.2% when anti-platelet therapy was applied, and by 16.2% when
anticoagulation therapy was used. None of the reviewed series, however, provided proof
of which modality was most effective, nor conclusive evidence on the reduction of the risk
of stroke, myocardial infarction or death among vascular patients.
The Dutch BOA study (2000) was a large randomised trial comparing oral anticoagulants
with ASA in infrainguinal bypass surgery. A total of 2690 patients were randomised and
followed for a mean of 21 months, graft occlusion being the primary outcome. Both
treatments were effective irrespective of the level of the distal anastomosis. In a subgroup
analysis, oral anticoagulation was more effective than ASA in preventing infrainguinal vein
bypass failure, but it caused more bleeding episodes. ASA was superior in preventing non-
venous graft occlusion, contrary to a number of local policies, by which ASA is commonly
used in all vascular patients and warfarin only in high-risk patients.
The recommendations of the APCC conference (2004) for vascular patients include
administration of ASA for all patients with chronic ischaemia, intermittent claudication, and
patients undergoing vascular reconstructions (Clagett et al. 2004). ASA is recommended
for patients with prosthetic bypass, but routine use of anticoagulation is not recommended
for venous bypass patients, presumably for fear of noncompliance and bleeding in this
elderly multimorbid patient population. Anticoagulation and ASA both are recommended
for high-risk patients only.
Clopidogrel is the latest anti-platelet agent with proved benefit in cardiovascular patients in
terms of risk reduction of vascular events (CAPRIE Steering Committee 1996). A
randomized trial by Smout et al. (2004) gave evidence to support long-term clinical
combination of ASA and clopidogrel in patients with peripheral vascular bypass grafts. The
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data from the CASPAR trial showed that when clopidogrel was combined with ASA, the
outcome in the group of prosthetic grafts was improved. There was no overall beneficial
effect of the use of clopidogrel and ASA for infrapopliteal venous bypass (Belch et al.
2007). Currently, clopidogrel is recommended only to patients intolerant of ASA or with a
history of coronary artery stenting (Dagher et al. 2007). A recently observed problem is the
nonresponsiveness to ASA or especially to clopidogrel in a number of patients with
atherothrombotic disease (Lepäntalo A et al. 2004).
6.4.2 Vein cuff
Due to the fact that a prosthetic graft is a suboptimal bypass graft, attempts to improve it
have been searched. A rigid non-compliant prosthesis is difficult to anastomose to a small
recipient artery. Furthermore, it was noted that intimal hyperplasia accumulated strongly
on the anastomosis area, especially in areas of low shear stress, i.e. at the heel and at the
floor of the anastomosis (How et al. 2000). Siegman first introduced the reconstruction of a
vein cuff at the distal anastomosis in 1979. Miller (1984) developed this idea further to a
venous collar, later called Miller cuff, at the distal anastomosis. The cuff aided the suturing
of the distal anastomosis because both the heel and the toe of the anastomosis were
clearly visible. Subsequently, different configurations of cuffs were introduced: the
Tyrrel/Wolfe cuff or St.Mary’s boot (Tyrrel & Wolfe 1991) and the Taylor patch (Taylor et al.
1992) among others. The rationale of the cuff was to inhibit intimal hyperplasia and thus
graft occlusion, even though it was not clear what caused the hyperplasia.
The effect of the venous cuff was also the focus of experimental studies. Tyrrel et al.
(1990) proposed that the vein cuff protected the anastomosis from mechanical distortion
and possibly acted as a reservoir for the flow. In their canine model, Norberto et al. (1995)
compared the compliant vein cuff with a jacketed non-compliant cuff, and found no
difference in the formation of hyperplasia. They concluded that the protective effect of the
cuff was not mechanical in origin. Kissin and coworkers (2000) compared the vein cuff with
a prosthetic cuff and with an end-to-side anastomosis without a cuff in an experimental
study. The vein cuff altered the site of the intimal hyperplasia thus sparing the recipient
artery. Despite the same configuration of the prosthetic cuff, it did not have the same
protective effect, leading to the conclusion that biological properties of the autologous
tissue were responsible for the protective effect.
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The haemodynamic studies by Cole et al. (2002) showed that the vein cuff caused
unfavourable flow conditions predisposing to intimal hyperplasia. The protective effect of
the cuff was therefore assumed to be caused by the venous material. In contrast to this,
How et al. (2000) compared cuffed and non-cuffed anastomosis in an experimental model
and showed that the altered site of shear stress in a cuffed anastomosis caused
redistribution of the myointimal hypeplasia away from the critical sites.
To determine the role of the distal vein cuff in adjunction with a PTFE graft, a randomised
controlled trial was published by Stonebridge et al. (1997). They reported on a group of
261 bypasses, 37% to below knee popliteal and 6% to crural vessels, which were
randomised to either the vein cuff group or the control group. There was no difference in
patency between the groups in the above knee bypasses, but in the below knee position,
the vein cuff resulted in significantly better patency and in 20% higher limb salvage. The
protective effect of the vein cuff was explained to be technical, facilitating the
reconstruction of the distal anastomosis.
Prosthetic bypass without adjunctive methods gives poor long-term results. Even though
the protective effect of the vein cuff has not been thoroughly explained, the results on
series with vein cuffs and on a randomised trial, indicate that the use of a vein cuff is
justified in a PTFE bypass to crural arteries. (Table V)
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Table V
Outcome of prosthetic bypasses with a vein cuff
PP PP PP PP PP PP SP SP SP LS LS LS LS LS LSAuthor No.ofbypasses CLI/SLI Cuff type Outflow 1-year 2-year 3-year 4-year 5-year 8-year 1-year 2-year 3-year 1-year 2-year 3-year 4-year 5-year 8-year
34% AK 91* - 81* - 71* 54* - - - 96* - - - 88* 80*
34% BK - - - - - - - - - - - - - - -
Taylor
et al 1992 256 72/28
Taylor
patch
32% IP 74 - 58 - 54 - - - - - - - - - -
Harris
et al 1993a 43 100/0
avf+
Miller cuff 100%IP - 61 - - - - - 62 - 61 - - - - -
57% AK 85 - 69 - - - - - - - - - - - -Raptis&Miller
1995 489 49/51
cuff or
patch 43% BK 83 - 57 - - - - - - - - - - - -
Sidawy 80 100/0 Taylorpatch 100%IP 82 78 70 63 - - - - - 88 83 79 79 - -
57% AK 80 72 - - - - - - - 86 84 - - - -
37% BK 80 52 - - - - - - - 86 82 - - - -
Stonebridge
et al 1997 133 89/11
Miller
cuff
6%   IP 47 ** - - - - - - - ** ** - - - -
16% AK - 75 - - - - - - - - 92 - - - -
33% BK - - - - - - - - - - - - - - -
Pappas
et al 1998 42*** 98/2
Miller
cuff
51% IP - 62 - - - - - - - - 65 - - - -
12% BK 96 45 38 - - - 98 47 47 92 92 92 - - -Kreienberg
et al 2000 59**** 100/0
Vein
cuff 88% IP - - - - - - - - - - - - - - -
Outcome endpoints are reported in percentages
CLI= critical leg ischaemia, SLI= symptomatic leg ishaemia, avf=av-fistula, AK= above knee, BK= below knee, IP= infrapopliteal bypasses
PP= primary patency, SP= secondary patency, LS= leg salvage
* patency for popliteal grafts and leg salvage for all grafts
** n too small to allow calculations
*** Warfarin in 69% of patients, patency and leg salvage calculated for popliteal and infrapopliteal subgroups
**** results for all grafts
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6.4.3 AV-fistula
End-to-side anastomosis between the graft and the recipient artery is most commonly
used in infrainguinal bypass surgery. This configuration allows blood to circulate both
through the new bypass conduit and through the remaining patent native vasculature.
Especially in the distal anastomosis, an end-to-side anastomosis allows blood to circulate
both antegrade and also retrograde if the outflow is compromised. Fisher et al. (2004)
studied the outflow distribution at the distal anastomosis of a bypass. The mean outflow
distribution was 75% to the distal direction and 25% to the proximal direction, with the
distal flow decreasing more, the more distally that the anastomosis was placed. These
observations suggest that when the distal outflow is poor, most of the flow is directed
retrograde to a limited outflow tract resulting in poor bypass graft flow.
Sauvage et al. introduced the theory of thrombotic threshold velocity (TTV) in 1979.
According to their theory and observations, there was a certain flow velocity for each graft
material below which thrombosis of the graft would occur. Prosthetic grafts required a
significantly higher flow to remain patent, whereas autologous arterial grafts remained
patent with almost no flow. Based on the TTV hypothesis, an adjuvant av-fistula was
combined to a prosthetic bypass to improve graft flow. The idea of the av-fistula is to
increase flow by reducing peripheral resistance. The fistula shunts part of the flow to the
low resistance venous circuit, short-circuiting the inadequate run-off, thus preventing
stagnant flow and thrombosis.
The adjuvant arteriovenous fistula was first used in experimental studies. The first
experimental canine models demonstrated increased graft flow (McGovern et al. 1985,
Gwynn et al. 1988), but also led to venous hypertension and retrograde distal flow. Due to
the worsened distal perfusion, the authors concluded that av-fistulas should not be used in
clinical practice.
In an experimental setting, Parvin et al. (1984) showed a flow increase of 900% in the
bypass graft when the av-fistula was made between the deep vein and artery proximal to
the site of the anastomosis. An electromagnetic flowmeter showed that the artery offered
adequate resistance between the distal anastomosis and proximal fistula, thus improving
the distal perfusion. In this study the optimal configuration of the fistula was determined by
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comparing different sizes and locations of the fistula. All fistulas increased bypass graft
flow, but distal perfusion was found to benefit most from the proximal av-fistula.
Paty et al. (1990) experimented with different sized distal av-fistulas and found that
increasing the fistula size caused a reversal of flow. In a 3 mm calibre artery, a 3-5mm
long av-fistula increased graft flow without reversing distal flow, which was noted with a
7mm long av-fistula. In their clinical series, a distal av-fistula increased graft flow and distal
perfusion, which was evidenced by duplex examination.
In addition to distal flow impairment, other adverse effects of the fistula were feared. Steal
is a phenomenon caused by the av-fistula when most of the graft flow is directed to the low
resistance venous outflow and the distal perfusion is compromised. When there is no
proximal stenosis, i.e. the inflow is adequate, steal does not occur (Moody et al. 1991,
Nielsen et al. 1996). Only anecdotal reports of excessive shunting exist (Teittinen et al.
1999). On the other hand, when the flow through the fistula increases, the distal perfusion
is impaired. In a study by Kallakuri et al. (2003) a flow above 1 l/min decreased distal
perfusion significantly. Such high flow values are, however, rarely encountered in
combination with bypass surgery and av-fistulas; usually even limited flow to the outflow
tract reverses the ischaemic state of the limb (Dardik et al. 1991).
Venous hypertension and extremity oedema may be encountered when the deep veins are
filled with arterial flow from the bypass graft. This rarely occurs if the deep vein system is
patent and the fistula flow is directed to the deep and not the superficial venous system
(Moody et al. 1991, Harris et al. 1993a). Banding of some portion of the av-fistula has
been proposed by some authors to prevent venous hypertension and steal (Jacobs et al.
1992, Ascer et al. 1996). In an experimental model Kallakuri and coworkers suggested
banding of the fistula in all cases to achieve a distal graft pressure of 100 mmHg (Kallakuri
et al. 2003). In clinical series the banding of the fistula has rarely been necessary (Dardik
et al. 1996).
Even cardiac overload is possible if the fistula is too large, causing shunting of excessive
amounts of blood. Flow values of 2 l/min or a 20% increase in cardiac output are needed
to increase the preload to the right ventricle and to cause cardiac failure. Generally cardiac
failure with adjuvant fistulas is rare, and has been described only in case reports (Teittinen
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et al. 1999). Adjuvant av-fistulas are usually well tolerated. The reported cardiac problems
have arisen from therapeutic av-fistulas in haemodialysis patients (Engelberts et al. 1995).
Ibrahim et al. (1980) presented one of the first series of patients in which clinical benefit
was achieved in conjunction with the use of an av-fistula: out of 13 patients with human
umbilical vein bypass in combination with an adjuvant fistula, limb salvage was achieved in
10 patients, and only one patient displayed the steal phenomenon. On the other hand,
Snyder’s group (1985) reported a series of 30 bypasses with initially augmented graft flow,
but poor long-term outcome, with a rate of only 20% leg salvage at two years. In a more
recent clinical series better outcome was achieved with the adjunctive fistula. (Table VI)
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Table VI
Outcome of infrapopliteal prosthetic bypasses with av-fistula
PP PP PP SP SP SP LS LS LSAuthor No.ofbypasses CLI/SLI
Type of
bypass Outflow 1-year 2-year 3-year 1-year 2-year 3-year 1-year 2-year 3-year
Paty et al 1990 16 100/0 PTFE +avf crural 67 - - - - - 75 - -
Moody et al 1991 80 100/0 HUV+avf crural 39 36 30 - - - 43 38 36
crural, 71 - - - - - 83 - -
Jacobs et al 1992 30 100/0 PTFE+avf
2 pedal - - - - - - - - -
76 PTFE+avf crural - 25 - - 28 - 38 35 -




1 pedal - - - - - - - - -
crural, 78 70 62 - - - 89 86 78*
Ascer et al 1996 68 100/0 PTFE+avf+cuff
3 pedal - - - - - - - - -
Dardik et al 1996 290 100/0 HUV+avf crural - - - 77 69 61 81 79 75
Sogaro et al 1996 91 100/0 HUV+avf crural 54 40 40 72 60 57 73* 62* 62*
crural, - 46 - - 65 - - 64 -
Eagleton et al 1999 43 100/0 PTFE+avf
3 pedal - - - - - - - - -
10% BK 86 73 48 86 73 48 84 76 76Kreienberg et al
2000 48 100/0 PTFE+avf 90% crural - - - - - - - - -
Biancari et al 2001** 12 100/0 PTFE+avf crural 67 - - - - - 100 - -
Outcome endpoints are reported in percentages
CLI= critical leg ischaemia, SLI= symptomatic leg ischaemia, HUV= human umbilical vein graft, avf= av-fistula, BK= below knee




Different types of fistula configurations have been described. Dardik et al. (1996)
described the common ostium av-fistula in combination with a human umbilical vein
bypass. In a report by Moody et al. (1991) the configuration of the fistula, either common
ostium or proximal, had no effect on patency. Sogaro et al. (1996) introduced a pantaloon
technique of an adjuvant fistula with HUV. Jacobs et al. reported (1992) a series of 30
patients with a PTFE crural bypass, a common ostium av-fistula and proximal vein ligation.
In a series by Ascer et al. (1996) an av-fistula was created first, after which the PTFE graft
was anastomosed to the hood of the av-fistula, and the distal vein was then ligated.
(Figure 1)
Figure 1. Different types of av-fistulas
A Common ostium av-fistula, B Proximal vein piggyback, C Distal vein piggyback, D Vein
interposition av-fistula, E Distal av-fistula, F Proximal av-fistula (modified from D’Andrea
et al. 1998)
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The haemodynamic changes caused by the fistula have also been investigated in clinical
series. Dardik et al. (1991) showed that the bypass graft flow improved, as demonstrated
by both angiogram and duplex examination, always with antegrade distal flow. His group
has also recorded the patency of the adjunctive fistula. Their observations demonstrated
that the fistula patency decreased during the follow-up, but this had no direct effect on the
graft patency, i.e. a number of grafts stayed patent despite the thrombosed fistula.
Jacobs et al. (1992) demonstrated the improved distal perfusion by ABI measurements. In
his later study of 26 patients with PTFE bypass with or without an av-fistula, the patients
with the av-fistula displayed significantly better patency and leg salvage. The
microcirculation of the foot was also improved as shown by the augmented capillary
perfusion (Jacobs et al. 1993).
Harris’ group (1993a) compared a PTFE bypass with an av-fistula to a cuffed PTFE
bypass and av-fistula and to a venous bypass. The patency of the cuffed PTFE bypass
with adjunctive fistula approached that of a venous bypass and was significantly better
than the non-cuffed PTFE bypass. They concluded that the two adjunctive methods, the
vein cuff and the av-fistula, might be synergistic.
Kreienberg et al. (2000) compared a PTFE bypass with either a vein cuff or an av-fistula,
and found limb salvage to be better in the vein cuff group. This was explained by the better
opportunity of revision in the case of failure in the vein cuff group.
Biancari and coworkers reported a series redo infrapopliteal bypasses in 2001 (Biancari et
al. 2001). In their series, the adjuvant av-fistula seemed to augment redo bypass graft
patency, but the survival of the patients with an av-fistula was significantly poorer than of
the patients without a fistula.
All these studies suggest that the av-fistula offers some benefit in terms of improved flow
and patency. The studies were, however, small case series. A randomised trial comparing
the av-fistula in adjunction with a PFTE bypass is needed.
The introduction of the in situ saphenous vein bypass technique allowed the effect of
residual av-fistulas to be studied, as a number of in situ grafts inevitably had residual
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connections from the arterialised vein to the venous tree. In comparison with reversed vein
bypass, it was anticipated that the residual av-fistulas would have a negative impact, if
any, on the outcome, contrary to the idea of improving flow in a prosthetic bypass with an
adjuvant fistula.
Chang et al. (1989) reported a series of 216 in situ bypasses which were followed up by
duplex examination. The flow through the fistula decreased significantly during the first
postoperative year, and was of haemodynamic significance in only 6.5% of the bypasses.
Haemodynamic significance was determined as persistent increasing fistula flow with or
without oedema and decreased distal resting flow or pressure measured by duplex or
pulse volume recording (PVR). When the haemodynamic criteria were met and fistula
ligation performed, distal bypass flow improved. In this study it was concluded that in the
majority of patients, the residual fistula had no clinical significance, whereas in patients
with reduced flow capacity, the redistribution of flow caused by the av-fistula was poorly
tolerated.
Lundell et al.(1999) studied 98 in situ bypasses for critical ischaemia. Residual av-fistulas
were found in 56% of the patients. About a quarter of these were surgically corrected due
to decreased flow velocity in the grafts distal to the residual av-fistula. The majority of the
residual fistulas did not require any procedures. Even though the distal flow velocity
decreased due to the residual fistulas, this did not always affect the distal perfusion as
demonstrated by the non-affected ABI. The criteria for a haemodynamically significant
residual fistula were therefore not clear.
Van Dijk et al. (1997) reported a series of 35 closed in situ bypasses. A total of 216 side
branches were coil-embolised and after this 39 residual av-fistulas were detected, and of
these, 11 symptomatic ones were treated. On the basis of these figures it was concluded
that it is unlikely for the av-fistulas to cause symptoms and thus repeat procedures.
The assumption made in all these studies was that residual av-fistulas would cause
decreased distal perfusion. The distal flow was shown to decrease in some cases, but the
ABI was not affected. However, none of these reports focused on the possible positive
effects of an av-fistula on venous bypass.
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6.4.4 Free flaps
The soft tissues in an ishaemic foot are limited, and rarely allow direct closure of tissue
defects. An ischaemic extremity may have a tissue defect that is so large that the wound
will not heal with conventional methods of revision and split thickness skin grafting. Local
cutaneous flaps of pedicular flaps can seldom be used due to the poor perfusion of the
limb. The reconstructive ladder presents the various options to achieve wound healing
from simple direct closure to microvascular free flaps (Mathes & Nahai 1997). In a PAD
patient the free flap may be the only alternative. Different types of free flaps have been
described to reconstruct foot tissue defects (Kaplan et al. 1998).
Figure 2. The reconstructive ladder (Mathes & Nahai 1997)
Special features are required from free flaps in the foot to allow healing of ulcers and
tissue defects and to achieve ambulation of the patient. Fasciocutaneous flaps are
proposed to provide the best contour in foot reconstructions (Rautio et al. 1989), but may
not tolerate ambulation well. There is a shearing effect between the fascia plane and the
skin and subcutaneous tissues during weight bearing. Therefore it has also been
suggested that a muscle flap with split thickness skin grafting yields best results in weight
bearing areas (Rainer et al. 1999).
Shestak et al. (1990) reported an indirect method of vascularisation of the extremity by
free flap transfer: When conventional bypass was not feasible, a vascularised flap was
placed to an ischaemic extremity, achieving foot salvage and resolution of symptoms. The
flap effect was explained by the improved run-off achieved by the flap. The “nutrient flap”
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was also described by Mimoun et al. (1989). In addition to providing a tissue cover, the
flap also provided supplementary blood flow to ischaemic areas, assisted in venous
drainage, and induced the formation of a capillary network.
Simultaneous vascular bypass and free flap transfer have been described in a number of
studies (Briggs et al. 1985, Gooden et al. 1997, Cronenwett et al. 1989, Lepäntalo
&Tukiainen 1996, Quinones-Baldrich et al. 2000). It has also been proposed that the
surgery should be staged: the vascular bypass should be done first, followed by the free
flap transfer (Greenwald et al. 1990). Simultaneous surgery extends the limits of limb
salvage with a cumulative 2-year limb salvage of 77-88% (Tukiainen et al. 2000,
Vermassen et al. 2000) and corresponding 5-year rates of 57-66% (Illig et al.
2001,Tukiainen et al. 2006). Due to the demanding nature of this combined surgery,
however, patient selection is crucial. The presence of diabetes and renal failure are strong
predictors of poor outcome. Illig and coworkers therefore suggested that these patients
should not be considered candidates for combined surgery (Illig et al. 2001). The presence
of heel ulcers and calcanear osteomyelitis are predictive of amputation, despite combined
surgery (Tukiainen et al. 2006).
Free flap transfer indirectly revascularises the extremity even without direct vascular
bypass. Serletti et al. (1995) found that in a number of cases in their series, combined
vascular bypass and flap transfer was not possible. They thus directed the vein graft inflow
to the free flap only, still achieving limb salvage. In a series by Tukiainen et al. (2006) a
subgroup of 13 patients did not have a suitable distal recipient artery; the bypass graft was
therefore anastomosed end-to-end to the flap artery directly. The limb salvage of this
subgroup did not differ from that of the rest of the patients. This procedure has been
described in case reports and explained by the ingrowth of the flap and resulting
neovascularisation into the surrounding tissues (van Landuyt et al. 1996a, Mätzke et al.
1997).
The blood flow in free flaps has been studied. Experimental models have demonstrated
that free muscle flap blood flow and capillary perfusion increase postoperatively. This is
thought to be caused mainly by the denervation of the flap (Chen et al. 1991, Siemionow
et al. 1994). Lorenzetti et al. (1999) studied blood flow in latissimus dorsi flaps, and noted
that the postoperative flap flow increased in the immediate postoperative period also in a
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clinical setting. This phenomenon helps to keep the microanastomosis open and is also
beneficial for wound healing. Flap flow in different types of flaps differs significantly. The
flow depends on the different tissue components of the flap, but it has also been noted that
the flap flow is not dependent on the recipient artery flow. The flow varies according to the
requirements of the free flap (Lorenzetti et al. 2001a).
When free flap transfer is connected to a bypass graft, the free flap has a significant
positive effect on the bypass graft flow. Van Landyut et al. (1996b) reported augmentation
of the graft flow, and suggested that the free flap increases the distal outflow bed without
the disadvantages of a conventional av-fistula, i.e. without shunting away of arterial blood
and causing venous hypertension. Lorenzetti et al. (2001b) reported a series of free flap
reconstructions in combination with a pedal vein graft bypass. In their study, the free flap
connected to the bypass increased the vein graft flow significantly. The free flap received
about a third of the total graft flow, the vein graft flow still being augmented. Thus the free
flap did not compromise the distal perfusion of the limb. It was proposed that the free flap
acted as an av-fistula, increasing the outflow bed and reducing peripheral resistance.
In a compromised situation the free flap connected to the vascular bypass graft seems to
improve the outflow status. It offers a flow reservoir by multiple possible mechanisms: the
ingrowth of the flap forms a capillary network, and the denervation of the flap causes
opening of subcutaneous av-shunts and increased flow through the transferred tissue,
which thus functions as an av-fistula. These phenomena seem to make the free flap a
haemodynamically promising method in augmenting vascular bypass graft flow by
enlarging the outflow bed.
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7. AIMS OF THE STUDY
The study investigates the effect of an adjuvant av-fistula on compromised infrapopliteal
prosthetic and venous bypass patency, and the possible impact of an adjuvant fistula on
leg salvage.
The following questions were posed:
1. The effect of an adjuvant av-fistula on prosthetic graft bypass patency.
2. The haemodynamic effects of an adjuvant av-fistula on a prosthetic bypass and its
possible adverse effects.
3. Effect of a radial forearm flap with an internal av-fistula connected to a vein bypass graft
on bypass graft haemodynamics and patient outcome.
4. Effect of a previous free flap transfer on a vascular bypass.
5. Potential benefit of an adjuvant av-fistula on a vein graft bypass with poor outflow.
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8. PATIENTS AND METHODS
All the patients in this study were operated on either by vascular surgeons, or in case of a
hybrid surgical procedure, together by a vascular and a plastic surgeon. The study design
was prospective in three studies (I, II, III), one study was a case report (IV) and one a
retrospective study (V).
8.1 PATIENTS
Study I: In this prospective randomised multicentre trial, 59 patients with critical leg
ischaemia and no suitable veins for grafting were recruited to receive a femorocrural PTFE
bypass with distal vein cuff, with or without an adjuvant av-fistula. 31 patients were
randomised to have an av-fistula, and 28 patients having a femorocrural bypass and distal
vein cuff without a fistula served as a control group.
Study II: A total of 50 patients from the two Finnish centres, i.e., Department of Vascular
Surgery, Helsinki University Central Hospital, and Department of Surgery, Etelä-Karjala
Central Hospital, that were involved in a prospective randomised trial, underwent an
extended follow-up including haemodynamic measurements. They comprised the patient
group in Study II.
Study III: Nine patients were treated with a modification of a standard technique of a radial
forearm flap. The flap included an internal av-fistula, and the free flap was used to cover a
tissue defect. All patients had large non-healing distal ulcers requiring both a vascular
bypass and free flap transfer. All the patients underwent a hybrid operation by a team
consisting of a vascular surgeon and a plastic surgeon at the Department of Vascular and
Plastic Surgery, Helsinki University Central Hospital.
Study IV: This study was a case report of a patient previously operated on for complicated
wound infection with a free flap transfer. The patient later needed a pedal bypass for CLI.
Study V: This study group comprised 77 patients who underwent an infrapopliteal
autogenous bypass procedure, which was complemented by an adjuvant av-fistula,
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because the bypass was considered to be at high risk for failure due to poor outflow. The
study was a retrospective multicentre study. Control patients randomly retrieved from the
three centres were matched with each case according to the outflow artery and run-off
score. The cases and controls were operated on during the same period. Table VII
presents data on operative activity in each of the study centres.
Table VII
Background data on the operative activity of the study population






Study I Helsinki, Lappeenranta
Västerås, Hillerod
1997-2000 983* 59 6
Study II Helsinki, Lappeenranta 1997-2003 453** 50 11
Study III Helsinki 1998-2003 40 / 790 *** 9 23 / 1.1
Study IV Helsinki 2005 case report 1
Study V Helsinki, Lappeenranta
Vaasa
1996-2003 1813* 77+77 4+4
* number of all infrainguinal bypasses for CLI during the study period
** number of all femorocrural bypasses for CLI during the study period
*** number of combined infrainguinal bypasses and free flap transfers / number of all
infrainguinal bypasses for CLI during the study period
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Demographics
Demographic data on the patients were collected according to the risk factors recorded in
the national vascular registry, Finnvasc database (Salenius 1992). The data were collected
prospectively, except for Study V which was a retrospective study. The data are presented
in Table VIII.
Table VIII














No. of patients 31 28 26 24 9 1 77 77
Sex: M / F 15 / 16 10 / 18 13 / 13 7 / 17 7 / 2 - / 1 42 / 35 37 / 40
Age: mean

















22 (71) 14 (50) 23 (88) 12 (50) 2 (22) - 45 (61) 42 (55)
Diabetes 12 (39) 12 (43) 12 (46) 12 (50) 9 (100) + 52 (70) 44 (57)
Hypertension 15 (48) 14 (50) 14 (54) 11 (46) 1 (11) + 31 (42) 28 (36)
Renal failure 2 (6) 2 (7) 2 (8) 1 (4) 1 (11) - 13 (18) 12 (16)
Preoperative ABI:
Median


















Rest pain 8 (25) 11 (39) 8 (31) 7 (29) - 7 (9) 14 (18)
Ulcer 16 (52) 14 (50) 14 (54) 14 (58) 9 (100) + 47 (61) 44 (57)
Gangrene 7 (23) 3 (11) 4 (15) 3 (13) - 23 (30) 19 (25)
Avf = arteriovenous fistula
Numbers in parentheses are percentages
*mean ABI of the patient group
** Defined by the standards proposed by the Ad Hoc Committee (Rutherford et al. 1997)
- Hypertension defined as blood pressure>165/95 mmHg or medication
- Renal failure defined as serum-creatinine>150ug/ml
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8.2 METHODS
8.2.1 Angiographic run-off score
The angiographic run-off score was determined according to the standards proposed by
the Ad Hoc Committee (Rutherford et al. 1997).
Studies I & II: The run-off score was evaluated preoperatively in 51 (86%) patients in Study
I and in 42 (84%) patients in Study II. The run-off was evaluated for both the recipient
crural artery and the pedal arch. Eight patients had poor angiographic data that did not
allow outflow scoring.
Study III: The extent of the vascular disease was assessed by angiography. DSA images
were scored by the method proposed by the Ad Hoc Committee (Rutherford et al. 1997).
Study V: The angiographic images were scored retrospectively by an experienced
angioradiologist blinded as to patient data. Intraoperative angiographic studies were used
as an aid for scoring in cases where the preoperative angiographic images were not
sufficient for scoring. The run-off scores were available for 56 (73%) patients from the
patient group with the av-fistula. Run-off data were available for the entire retrieved control
group. Control patients for the cases without a run-off score were selected from a sample
of controls with run-off scores ranging from four to ten. The frequency of the different run-
off scores in the av-fistula group was thus matched with that of the control group.
8.2.2 Surgical procedure
Studies I & II: The surgical procedure was carried out with a 6 mm externally supported
PTFE prosthesis. An interposition vein cuff was constructed in all cases at the distal
anastomosis. Patients randomised to the fistula group received an av-fistula of either the
common ostium type or proximal type according to the surgeon’s discretion. The patients
were operated on as a part of daily hospital routine. Any vascular surgeon with previous
experience of three or more av-fistulas was accepted to perform these operations.
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Study III: A two-team approach was used in all cases. First, a radical wound excision was
performed. The operation was then continued in two separate fields. The vascular surgeon
performed the distal bypass, and the plastic surgeon raised the fasciocutaneous radial
forearm flap. The internal fistula within the flap was created by performing an end-to-end
anastomosis between the distal end of the radial artery and the cephalic vein, or the
concomitant vein of the radial artery. The flap artery was anastomosed end-to-side to the
vein graft in eight cases, and in one case the flap artery was directly connected to the vein
graft because a distal bypass was not possible. The outflow of the flap was directed to a
deep vein of the limb. The flap was fixed into place and the wound closure was completed
with a meshed split thickness skin graft if necessary.
Study IV: In this case study a femoropedal bypass was performed with a saphenous vein
graft in a patient who 13 years earlier had been operated on for a complicated ankle
fracture with a latissimus dorsi (LD) free flap transfer.
Study V: An infrapopliteal vein graft bypass was performed in all cases. Only patients with
an autogenous vein graft bypass to either a crural or a pedal artery with an adjuvant av-
fistula were included in the study group. The patients in the control group were matched
according to the outflow artery.
The vein cuffs used in this study were either the Miller cuff or St. Mary’s boot (Miller et al.
1984, Tyrrel & Wolfe 1991). The av-fistula configurations were of the common ostium,
proximal or modified type (see Figure1: A, D, F). The internal av-fistula within the radial
forearm flap was created between the distal end of the radial artery and the cephalic vein
(Figure 3). The operative data are presented in Table IX.
Systemic heparin was given to all patients before arterial cross clamping. A prophylactic
antibiotic was administered according to hospital routine, or to bacterial cultures in patients
with infection. Low molecular weight heparin (LMWH) was administered postoperatively
until the patients became ambulatory. ASA medication was started for life, unless the
patient was on anticoagulation medication.
The free flap transfer patients were monitored in the intensive care unit or the recovery
room for the first 24 hours to ensure the vitality of the flap. These patients were kept in bed
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rest for seven days with the limb elevated. Ambulation was started gradually with










Study III Study V
Avf group Control
group
No. of bypasses 31 28 26 24 9 77 77
Inflow:
Common femoral 31 23 26 20 4 28 42
Prosthesis* - 5 - 4 - - -
SFA - - - - 2 29 16
AK popliteal - - - - - 5 3
BK popliteal - - - - 3 15 16
Outflow:
ATA 13 13 9 12 - 5 5
ATP 8 7 7 5 3 6 6
Fibularis 10 8 10 7 1 8 8
ADP - - - - 2 42 42
Plantaris - - - - 2 16 16
Other** - - - - 1 - -
Graft:
PTFE 31 28 26 24 1*** - -
Vsm - - - - 8 63 67
Arm vein - - - - 1*** 9 2
Spliced vein - - - - - 5 8
Cuff:
Miller 16 16 14 16 - - -
St. Mary’s boot 11 9 8 5 - - -
Other 4 3 4 3 - - -
Av-fistula:
Common ostium 25 - 20 - - 60 -
Proximal 6 - 6 - - 9 -
Other - - - - 9a 8b -
Avf = arteriovenous fistula
* inflow from a previous prosthesis at the femoral level
** outflow from the vein graft directly to the flap artery
*** femoropopliteal PTFE graft with an arm vein jump graft
a internal av-fistula in the radial forearm flap
b a modified fistula: the fistula was made directly on the vein graft on the distal anastomosis without
re-doing the entire anastomosis
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Figure 3. Schematic illustration of the modified radial forearm flap with the internal av-











8.2.3 Intraoperative flow measurements
Study II: Intraoperative flow measurements were done to evaluate the haemodynamic
effect of the fistula. The flow measurements were performed with a transit time flowmeter
(CardioMed CM4006, Medistim A/S, Oslo, Norway) at the end of the operation when the
distal anastomosis was completed and flow opened and stabilised. Outflow to the recipient
artery and to the fistula was recorded separately, as well as the maximal flow capacity
after intragraft injection of papaverin hydrochloride (40 mg). The maximal flow capacity
was recorded with the fistula closed in the av-fistula group. Systemic blood pressure and
pressure at the inflow artery were registered intra-arterially to reveal a possible gradient
indicating proximal stenosis.
Study III: Flow measurements were recorded during the surgery. A transit time flowmeter
was used. The flow in the radial artery was measured when the flap was raised while the
vascular pedicle was intact, with the fistula both open and closed. The graft flow was
recorded prior to the flap transfer. After the flap was fixed on the foot, anastomoses were
completed and the flow stabilised. The flow to the graft and to the flap artery were
recorded with the av-fistula both open and closed.
Study IV: The flow was recorded after the completion of the distal anastomosis according
to hospital routine, using a transit-time flowmeter.
Study V: In this study the flow was recorded with a transit-time flowmeter after the
completion of the distal anastomosis. If the patient was considered haemodynamically
stable, the maximal flow capacity (MFC) was recorded after an intra-arterial injection of
papaverin hydrochloride (40 mg). In 12 patients with an av-fistula, flow recordings were
taken both prior to and after the reconstruction of the av-fistula. Flow measurement
recordings were available in 39 cases in the av-fistula group and in 61 cases in the control
group, because the data were collected retrospectively.
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8.2.4 Follow-up
Study I: The follow-up was at regular intervals according to a surveillance schedule.
Clinical outpatient visits with ABI measurements and duplex graft surveillance took place
at 7 days, 1, 3, 6, 9, 12, 18 and 24 months postoperatively.
Study II: The same schedule was applied, with extended follow-up every six months after
two years. Duplex examinations with graft velocity measurements were performed and the
circumference of the legs was recorded in addition to other clinical data. The follow-up
time ranged from 40 to 75 months.
Study III: The first follow-up visit was at 1 to 2 months postoperatively, and thereafter at 3,
6 and 12 months, and once a year, depending on the healing of the foot. The follow-up
time varied between 14 and 51 months.
Study IV: The patient was assigned a follow-up schedule according to hospital routine: at
1, 3 and 6 months, and every 6 months thereafter.
Study V: All three units utilised the same graft surveillance schedule. During the first
postoperative year the visits were at 1, 3 and 6 months, after which the patients were
generally surveyed every 6 months with clinical outpatient visits, ABI measurements and
duplex examinations of the grafts. The follow-up time ranged from 2 months to 8 years.
8.2.5 Statistical analysis
The statistical analyses were conducted with SPSS statistical software (ver 9.0, 11.0, 14.0,
SPSS Inc, Chicago, Ill., USA). Primary and secondary patency, leg salvage and patients
alive with a leg were analysed by the life table method. Kaplan-Meier analysis and the log-
rank test were applied to test for statistical significance (I, II, III, V). Fisher’s exact test was
used for the analysis of categorical data (I). The Mann-Whitney U test and Chi-square test
were used for the analysis of nonparametric and categorical data, as appropriate.
Correlation analysis was done using bivariate correlation and Spearman’s correlation
coefficient (II). The Chi-square test, the Wilcoxon test and the Mann-Whitney U test were
used in analysis of the nonparametric data and the parametric data with a skewed
distribution (III, V). Statistically significant differences were given with p-values less than




Our results revealed that there was no difference between the av-fistula group and the
control group in terms of patency. The cumulative primary and secondary patencies were
29% and 40% in the av-fistula group, and 36% and 40% in the control group at two years
(p=0.77 and 0.89). (Figure 4)
Leg salvage at two years was 65% and 68%, respectively. 54% of the patients in the av-
fistula group, and 48% in the control group were alive without amputation in the same
period. (Figure 5)
The av-fistula did not have negative effects on the distal perfusion, as shown by the
average ABI increase from the preoperative level of 0.55 in the av-fistula group and 0.57 in
the control group at one month.
The operation lasted 222 minutes (median) in the av-fistula group, and 180 minutes in the
control group (p=0.04).
The patency of the av-fistula was recorded by duplex surveillance in 19 patients available
for surveillance at one year. Four of the original 31 av-fistula patients were amputated,
three were dead, three had occluded grafts, and two patients were not available for
surveillance. In six cases there was an occlusion of the av-fistula, and in only one case this
resulted in graft thrombosis, which after reoperation led to leg salvage. Five patients had a
record of a previously patent fistula but had had graft failure at one year. These data on
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Avf group   31      22        20      19        14       12     11        10        9
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At three years, the primary and secondary graft patency rates in the av-fistula group were
21% and 24%, and in the control group 33% and 43 %, respectively. The difference did not
reach statistical significance. (Tables X & XI)
Table X
Primary patency rates in the av-fistula group and the control group (Study II)
AVF group






0-1 26 5 1 0.81 7.8
1-3 20 2 2 0.72 8.9
3-6 16 1 0 0.68 9.4
6-9 15 3 0 0.54 10.3
9-12 12 2 0 0.45 10.4
12-18 10 2 0 0.36 10.1
18-24 8 1 3 0.32 9.8
24-30 4 1 1 0.21 10.8
30-36 2 0 1 0.21 10.8
Control group






0-1 24 5 1 0.79 8.3
1-3 18 1 0 0.75 8.9
3-6 17 4 0 0.57 10.3
6-9 13 1 0 0.53 10.4
9-12 12 0 1 0.53 10.4
12-18 11 3 0 0.38 10.4
18-24 8 0 1 0.38 10.4
24-30 7 1 1 0.33 10.2
30-36 5 0 0 0.33 10.2
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Table XI
Secondary patency rates in the av-fistula group and the control group (Study II)
AVF group






0-1 26 2 1 0.92 5.3
1-3 23 2 2 0.84 7.3
3-6 19 1 0 0.80 8.2
6-9 18 4 0 0.62 10.1
9-12 14 2 0 0.53 10.4
12-18 12 2 0 0.44 10.4
18-24 10 0 3 0.44 10.4
24-30 7 1 2 0.35 11.5
30-36 4 1 1 0.24 12.3
Control group






0-1 24 3 1 0.88 6.8
1-3 20 1 0 0.83 7.7
3-6 19 3 1 0.69 9.7
6-9 15 1 0 0.65 10.1
9-12 14 0 1 0.65 10.1
12-18 3 4 1 0.43 11.1
18-24 8 0 1 0.43 11.1
24-30 7 0 1 0.43 11.1
30-36 6 0 0 0.43 11.1
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Leg salvage
The groups fared equally well as regards leg salvage and survival. Three-year leg salvage
was 64% for the av-fistula group and 71% for the control group (p=0.44). At three years,
58% and 54% of the patients were alive, respectively. At five years the survival rate was
49% and 36%, respectively. Altogether 35% and 42% of the patients were alive with a















































Figure 6. Long-term leg salvage, survival, and patients alive with a salvaged leg: av-fistula




The intraoperative graft flow values varied widely, the median being 110 ml/min (range 11-
600). There was no significant proximal gradient between systemic and inflow artery blood
pressure (mean 7.9 mmHg). There were 8 immediate graft failures (<30 days). The
median flow value in the immediate success group was 115 ml/min (range 20-600)
compared to 65 ml/min (range 11-250) in the group of 8 failed grafts (p=0.1).
The flow values in patients with an av-fistula were significantly higher (p=0.009) than in the
control group (181 vs 80 ml/min). However, when flow directed to the outflow vessel was
registered separately with the fistula closed, this difference in outflow values between the
groups disappeared (93 vs 80 ml/min, p=0.59). (Figure 7)
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Figure 7. Total graft flow in the av-fistula group and the control group, and flow to the
outflow artery, when the av-fistula was temporarily closed in both groups. (Study II)
There was no difference between the patients with or without an av-fistula in terms of
maximal flow capacity after papaverin injection (125 vs 131 ml/min, p=0.55). The group of
patients with immediately patent grafts responded better to papaverin (131 vs 65 ml/min).
This points to a better run-off and thus a better prognosis in terms of patency (p=0.08).
(Figure 8)
p= 0.009 p= 0.59
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Figure 8. Graft flow at rest and after i.a. injection of papaverin in subsequently patent and
occluded grafts. (Study II)
When the flow values were compared to the preoperative run-off scores, no correlation
was found (r=0.17, p=0.25).
In the group of patients with an av-fistula the flow values of the failed and patent grafts did
not differ (189 vs 115 ml/min, p=0.23). Furthermore, whether most of the flow was directed
to the fistula or to the outflow vessel had no effect on patency. When a low flow value of 50
ml/min was used as a cut-off point, patients with a flow level higher than 50 ml/min had
significantly better immediate patency than patients with a flow beneath this level
(p=0.025).
Postoperative graft flow
In the postoperative duplex surveillance, there was a statistically significant difference in
terms of maximum flow velocity (Vmax) between the av-fistula and control groups at one
month (104 vs 65 cm/s, p=0.04), which disappeared in the subsequent examinations (82
vs 89.5 cm/s, p=0.83 at three months). When the Vmax values for the grafts that later
occluded were compared with the grafts that remained open, there was no statistical
difference between the two groups. Under the 12-month surveillance period the median
Vmax value for the av-fistula group was 80 cm/s (range 39-200) and 65 cm/s (range 0-
p= 0.1 p= 0.08
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180) in the control group (p=0.08). Median Vmax values for the patent and later occluded
grafts were 80 cm/s (30-200) and 70 cm/s (0-180), respectively (p=0.30). (Figure 9)
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Figure 9. Graft flow in the duplex examination at one and at three months in the av-fistula
group and the control group. (Study II)
In the immediate postoperative period, the greater graft flow correlated with the
circumference of the leg in the av-fistula group (r= 0.68, p=0.03). This was not observed in
later measurements.
Pressure response
An average ABI increase of 0.61 was recorded in the av-fistula group, and of 0.54 in the
control group immediately after operation. Toe pressure was increased by an average of
47 and 50 mmHg in both groups, respectively. The ABI increase was similar in the groups
of grafts that stayed patent, as well as in those with subsequent early failure (p=0.22).
p= 0.04 p= 0.83
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Adjuvant av-fistula patency
In a subgroup of patients under surveillance for patency of the av-fistula, the graft was
found patent in 41% at one year, whereas patency of the fistula was only 30%. At two






























0-1 18 1 0 0.94 5.4
1-3 17 4 1 0.72 10.6
3-6 12 3 0 0.54 12.0
6-9 9 2 0 0.42 12.0
9-12 7 2 0 0.30 11.2
12-18 5 1 1 0.24 10.4




Calf and ankle circumferences were measured at each visit to find out possible oedema
caused by the av-fistula. The greatest circumference of the operated leg was compared to
that of the non-operated leg to standardise the measurement. The difference between
these was the parameter to be followed. In subsequent measurements, the circumference
of the operated leg tended to be greater than the preoperative measurement in the av-
fistula group, but this difference did not reach statistical significance. When the
circumference of the operated leg was compared to that of the non-operated leg at every
measurement point, the only difference that was nearly statistically significant was found at
12 months when the difference in circumference was greater in the av-fistula group than in

































Figure 11. Leg circumference measured in both groups up to 24 months. (Study II)
Adverse effects
One patient with an av-fistula had static excema and swelling in the operated leg. At one
month the diameter of the operated leg was 7 cm greater than that of the non-operated
leg. At re-operation, the flow in the fistula was found to be 700 ml/min. The patient’s
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symptoms resolved after closure of the fistula, and the leg circumference returned to the
preoperative level.
Study III
Patency of the flap artery and bypass graft
There was one immediate (<30 days) flap failure. Despite the patent bypass graft, the flap
artery thrombosed and the flap was lost.
In one patient the vein graft occluded two months after the operation. The graft occlusion
led to flap artery occlusion, and later to below knee amputation.
Flap artery and graft patency were thus 78% and 89%, respectively, at two years.
Leg salvage
Two patients underwent below knee amputation in the immediate postoperative period
because of persistent infection despite patent grafts and vital flaps. Another major
amputation was required due to infection at 13 months.
Altogether four limbs were amputated during the follow-up: in addition to the one limb lost
due to flap artery thrombosis, three limbs had to be amputated due to infection. The limb
salvage rates at one and two years were 67% and 53% respectively.
Impact of internal fistula on flap artery and bypass graft flow
Median flow through the radial forearm flap while it was still in the arm was 8 ml/min (range
4-12) and it increased to a median of 58 ml/min (range 31-110) after the internal av-fistula
was created.
Median vein graft flow prior to flap transfer was 44 ml/min (range 20-60). The vein graft
flow increased almost twofold after the radial forearm flap anastomosis, the median flow
being 76 ml/min (range 32-105, p=0.016).
The flow through the flap artery after the anastomosis to the foot was 45 ml/min (range 13-
108) with the av-fistula open, but when the av-fistula was temporarily closed, the flow was
only 9 ml/min (range 3-15). There was no difference in the flow values of the artery of the
flap regardless of whether it was on the arm or transplanted to the foot (p=0.43).
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The median flows in the bypass graft and in the flap artery were significantly higher (76
ml/min and 45 ml/min, respectively) with a patent fistula than when the fistula was














Figure 12. Flow in the vein graft and the flap artery with the internal av-fistula open (+) and
temporarily closed (–). (Study III)
Study IV
After the completion of a femoropedal bypass, a high flow value for a pedal bypass graft of
200 ml/min was measured with a transit time flowmeter. A completion angiogram revealed
poor outflow but a patent vein graft.
The postoperative ABI was 1.09 and the toe pressure 118 mmHg. A very high amplitude
pulse volume recording was seen in the postoperative ABI measurements. (Figure 13)
A high flow of 100 cm/s was measured in the postoperative duplex ultrasonography
examination in the bypass graft at one month.
p= 0.016 p= 0.004
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During the follow-up the ABI increase was sustained with ABI of 1.38 and toe pressure of
124 mmHg. The status of the graft was checked with duplex ultrasonography and the graft
was found patent with a flow of 70-100 cm/s.
Figure 13. Pre- and postoperative pulse volume recordings and pre- and postoperative





There was no difference in patency between the two groups during the follow-up. Primary
patency of the vein graft was 61% and 49% at one and three years, respectively, in the av-
fistula group, and 57% and 46% in the control group during the same time period. Assisted
primary patency and secondary patency were 67% and 75% at one year and 58% and
62% at three years, respectively, for the av-fistula group. Assisted primary patency and
secondary patency for the control group were 70% and 71% at one and three years,
respectively. (Figure 14)
Leg salvage
The leg salvage rate was 83% and 76% at one year and three years in the av-fistula group
compared to the 87% leg salvage rate of the control group. The survival of the patients
was 79% and 52% at one and three years, respectively, for the av-fistula group, and 85%
and 58% for the control group. Accordingly, the amputation-free survival for the av-fistula
group was 64% and 40% at one and three years, and 77% and 54% for the control group
in the same time period. (Figure 15)
Impact of run-off score on patency
In the group of patients with an av-fistula, 49 (88%) out of 56 angiographies sufficient for
scoring had a run-off score of seven or more. The run-off scores of the control group were
similar to those of the av-fistula group. There was no difference in the run-off score
between the patients with patent grafts and immediately occluded grafts (p=0.79) in either
group, nor in the analysis of the whole patient population. When a cut-off value of seven
was tested, there was no difference in terms of patency between the patients with the run-
off score of at least seven or lower than seven (p=0.92).  Furthermore, the patients with a
completely obstructed pedal arch (giving a run-off score of 10) achieved patency rates
equalling those of the rest of the study group.
Pressure response
The median increase in ABI was similar in both groups: 0.6 in the av-fistula group and 0.62
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The median graft flow after the completion of the fistula was significantly higher in the av-
fistula group than the in the control group (110 ml/min (range 10-400) vs 60 ml/min (range
10-176, p=0.001). In a subgroup of 12 patients the flow was measured both prior to the
reconstruction of the fistula and after it, giving median flow values of 20 ml/min (range 10-
60) and 115 ml/min (range 10-350) respectively. The difference was statistically significant
(p=0.003).
Regardless of the av-fistula, after the papaverin-induced vasodilatation, the flow values
increased equally in the two groups according to recorded MFC. (Figure 16)
The patency rates did not differ between the pedal and the crural bypasses in either the
av-fistula or the control group (p=0.84), even though there was a significant difference in
the respective median graft flows (60 ml/min vs 93 ml/min, p=0.003).
The patients whose grafts had failed immediately tended to have lower flow values (29
ml/min vs 80 ml/min, p=0.07). Despite the reconstruction of the fistula, the flow values did
not increase in some patients in the group of failed grafts. In the control group, three
patients had a low flow value (<20 ml/min) after the completion of the distal anastomosis;
this would have been considered an indication to reconstruct an av-fistula in the av-fistula
group. However, these patients had, a good vasodilatation response to papaverin.
75














Figure 16. Graft flow in both groups at rest, and the maximum flow capacity after intra-




10.1 LIMITATIONS OF THE STUDY
Studies I and II: A total of 59 patients were recruited to a randomised prospective trial with
strict inclusion and exclusion criteria. This Scandinavian multicentre pilot trial was
undertaken to compare a 6 mm PTFE graft with a distal vein cuff, and an adjuvant av-
fistula with a similar graft without a fistula. The aim was to find out whether patients with
the adjuvant fistula might have better 2-year graft patency and leg salvage, and if so,
whether the results would indicate a need to shed light on the causes of the difference in a
larger multicentre study with sample size calculations aided by the results of this pilot
study. Since there was no difference between the groups at two years, and another study
had also revealed similar outcome results (Hamsho et al. 1999), there was no reason to
start planning a randomised major scale study despite the possibility of a type two
statistical error.
Study III: A novel technique of flap coverage was introduced in this study and therefore the
number of patients is very small. The results were presented with the life table analysis,
the validity of which is open to criticism in this kind of small series.
Study IV: This study is a case report. Objective observations were made on a single
patient, so generalizations cannot be made on the basis of these findings.
Study V: This was the first reported series of vein graft bypasses with an adjuvant av-
fistula. Because the series was a retrospective case series with matched controls, it is able
to provide level III evidence at best. Due to the small sample size, the study may be prone
to a type two statistical error.
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10.2 GENERAL DISCUSSION
In suboptimal circumstances, adjunctive methods to improve the outcome are searched.
With a prosthetic graft or with poor outflow and a low graft flow, the risk for failure is high.
The adjuvant av-fistula is believed to increase graft flow, hopefully to a level that results in
improved long-term patency. The av-fistula was first used in combination with
thrombogenic prosthetic grafts, and it seemed to improve patency and outcome. In clinical
series, augmented graft flow was achieved with hardly any adverse effects. The true effect
of the fistula needed to be determined more specifically, however.
Our randomised controlled study revealed that the av-fistula did not improve the outcome
of the prosthetic bypass with a distal vein cuff. This was a result which we had not
anticipated. Hamsho and coworkers (1999) came to the same conclusion in their
randomised study. The distal perfusion was improved in haemodynamic measurements
despite the adjuvant fistula, and the flow values were significantly augmented. The distal
flow was antegrade, the ABI increased, and only one patient had symptoms indicating
adverse effects of venous hypertension. The only significant finding in the flow
measurements was, however, that a low flow value below 50 ml/min predicted graft failure
and was significant according to the outcome. This applied to both the av-fistula group and
the control group.
The patency of the av-fistula was also recorded. These data showed that even when the
av-fistula thrombosed, the graft could remain patent. In a patient with a large fistula
causing venous stasis, the fistula was ligated without subsequent occlusion. In contrast to
the results presented here, Dardik et al. (1991) showed that graft patency was
accompanied by fistula patency. They concluded that increased graft flow caused by the
fistula aided graft patency. Ascer et al. (1996) reported that the patency of the adjuvant
fistula declined. Their interpretation was that in the early phases the fistula patency aided
the graft patency and later on despite the thrombosis of the av-fistula, the threshold of the
graft to tolerate low flow would increase. The benefit of the fistula on prosthetic graft
patency is unclear, as there is no evident clinical benefit to be shown. The higher graft flow
might nevertheless help to keep some risky bypasses open long enough for the ischaemic
lesions to heal. It is known that some patients, whose skin lesions have healed, may
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tolerate graft failure even though operated on for critical ischaemia. This has recently been
a commonly used argument to advocate endovascular treatment, although lacking sound
evidence and open to serious debate (Lepäntalo et al. 2007). Since the av-fistula does not
improve prosthetic graft patency, the only indication to use a prosthetic graft in
infrapopliteal bypass surgery would be to avoid amputation in patients who have no
autogenous graft material.
Both distal ischaemia causing extensive tissue damage and concurrent infection resulting
in microthrombosis decrease the distal outflow bed. This may lead to the development of a
very limited outflow tract. The free flap transfer functions as a large av-fistula with open av-
shunts due to the vasodilatation caused by the denervation of the flap. The flows in the
muscle flaps differ. For instance, the LD flap has a flow of 50 ml/min, and thus it can be
seen as a well functioning av-fistula (Lorenzetti et al. 1999). The radial forearm flap acts as
a poor av-fistula, and we therefore introduced a new technique by which an internal av-
fistula was created within a radial forearm flap. The rationale of this was to decrease the
resistance in the poor run-off situation. The low-flow radial forearm flap was transformed
into a high-flow flap to augment the bypass graft flow. Acceptable results were achieved in
a small patient group: the radial forearm flap doubled the bypass graft flow. In a previous
series of Lorenzetti et al. (2001) the latissimus dorsi musculocutanous flap increased the
graft flow by 50%. The LD flap is a high-flow muscle flap, but a radial forearm flap with an
internal av-fistula functioned as an even better av-fistula by increasing the graft flow by
100%.
The free flap transfer has, however, also other properties by which it affects the outcome.
The ingrowth of the flap results in a microcirculatory capillary network that improves the
outflow bed. The flap carries nutrients and antibiotics to the infected wound bed and thus
aids in the wound healing (Mimoun et al. 1989).
The published studies have shown that free flap transfer in combination with a vascular
bypass augments graft flow intraoperatively (Lorenzetti et al. 2001). The long-term effect of
a free flap, however, has not been assessed thus far. In our case report the effect of a free
flap transfer performed 13 years earlier was recorded. The preoperative angiogram
visualised almost no outflow bed, and despite this, a very high bypass graft flow and pulse
volume recordings indicating a large av-fistula were achieved. The LD flap had grown into
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the recipient wound bed forming a capillary network which functioned as a large av-fistula
enabling a high graft flow.
The free flap transfer may have the positive effects of an adjuvant av-fistula without the
adverse effects of the latter. The denervated free flap causes vasodilatation and reduced
resistance, leading to improved bypass graft flow. The negative effects of an av-fistula
such as steal or venous hypertension are not, however, encountered because the free flap
functions as a transplanted organ with its own circulatory bed. In selected cases the free
flap transfer may therefore be significant to the patient by increasing the bypass graft flow
sufficiently to result in leg salvage.
Despite the development and possibilities of imaging techniques, the outflow bed of a
distal bypass cannot be accurately determined. The flow in very small arteries can be
identified by the duplex technique. However, this technique is not able to give an exact
morphological image. Whenever contrast media is used, whether in digital subtraction
angiography (DSA), computer tomographic angiography (CTA) or magnetic resonance
angiography (MRA), there is a possibility that not all vessels are visualised due to wrong
timing, arterial spasm, low concentration of the contrast media or other technical problems
(Hingorani et al. 2007). Four-planar DSA is imperative for obtaining the best possible data
on pedal vasculature. The assessment of the outflow is as accurate as the imaging
technique. The outflow is unfortunately one of the main determinants of outcome, so an
exact image would help in the planning of a bypass.
Due to problems in imaging techniques, there are clinical situations in which the status at
the operation is worse than anticipated. Consequently, means of rescue are needed to
avoid immediate vein graft failure. It can, of course, be questioned whether this is due to
poor patient selection. However, in these situations an adjuvant av-fistula again may offer
an option to achieve better flow and thus possibly a better outcome. There are no previous
reports of an adjuvant av-fistula in combination with venous bypass, and this is partly
because a vein graft tolerates relatively low flow.
In these extremely poor situations encountered in our clinical series, we attempted to
achieve better results by using an adjuvant fistula. The results obtained with the av-fistula
group were promising with relatively good patency and leg salvage, taking into account the
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outflow status. There was, however, no significant difference between these patients and
the matched controls in regard to either patency or leg salvage. Even in a patient group
with poor run-off, acceptable long-term patency and leg salvage was achieved. This
justifies the active policy concerning the use of infrapopliteal autogenous bypass in the
study centres.
Vein grafts may remain patent even with very low flow, as demonstrated by Stirnemann et
al. (1994). In Sauvage’s experimental study, an arterial allograft stayed patent even with
no flow (1979). Intraoperative flow values of crural bypasses were predictive of outcome in
a study by Albäck et al. (2000), but no significant cut-off value was found for pedal
bypasses. This may reflect the difficulty to determine the outflow potential of very distal
bypasses. The large muscles in the crural area provide an additional outflow bed, which is
not present in the pedal area.
Dardik and his coworkers reserve the use of an adjuvant fistula to human umbilical vein
bypasses to a limited outflow in the crural area. The compliant HUV prosthesis is proposed
to perform better than a noncompliant PTFE, and thus give better results. The compliance
of a graft is therefore suggested to be critical to patency. Because autogenous veins are
compliant, an adjunctive fistula in these bypasses would rarely be necessary, but in
selected cases it might prevent failure according to Dardik et al. (2007).
The angiographic run-off score did not predict patency in our study, as even grafts with an
extremely poor angiographic score and occluded pedal arch stayed patent. The quality of
the angiographic images may, of course, be questioned, as four-planar images were not
available on the outflow tract at the foot level during the study period. Additionally,
angiographic images provide only morphological information, which cannot be directly
interpreted as a functional measure of the distal arterial tree.
Intraoperative flow and peripheral resistance may provide better assessment of the true
run-off capacity. In their study, Peterkin et al. (1988) found that the peripheral resistance
correlated, to a limited extent, with the angiographic images. They observed that a number
grafts stayed patent despite limited run-off in angiography and high peripheral resistance.
In contrast, Lundell and Bergqvist (1993) found a high peripheral resistance and low flow
to be predictive of graft failure. In our present study the graft flow was significantly
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increased in the intraoperative flow measurements in the group with the fistula. The
maximal outflow capacity was, however, equal in the two groups despite the av-fistula. The
flow in the group of failed grafts was lower than in the grafts that stayed patent. It thus
seemed that a high enough rest flow and the vasodilatation effect predicted good patency.
A good response in maximal flow capacity measurements caused by an intra-arterial
injection of papaverin predicted graft patency in a study by Albäck et al. (2000). Davies
and coworkers (1993) also used the maximal flow value and found that patients with a
good haemodynamic response had a better outcome. In our study, it was obvious that the
adjuvant av-fistula augmented the graft flow in intraoperative measurements, but this did
not result in clinical benefit. The vasodilatation effect was equal in both groups, possibly
indicating that the outflow bed has a certain capacity beyond which it cannot be
manipulated by adjunctive measures. The papaverin response might therefore be the best
predictor of graft patency, as it seems to reflect the maximal outflow capacity of the
bypass.
With the caveat of statistical type II error, it seems that an adjuvant av-fistula does not offer
any benefit on the outcome of either prosthetic or autologous vein bypass grafting.
The internal av-fistula in a free flap transfer or a large free flap function in a manner similar
to that of an av-fistula, i.e. they increase the outflow bed and thus the bypass graft flow.
There is no evidence, however, on the true effect of the free flap on graft patency, which
should be determined in a larger scale study with flow measurements and long-term follow
up. Enormous effort would be needed to launch and follow through a randomised
multicentre study with a large number of patients in order to determine the effect of an av-
fistula on bypass grafting with statistically valid results. Because these patients are rather
infrequent, managing such a study would be unrealistic.
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11. CONCLUSIONS
1. An adjuvant av-fistula does not improve the patency of a femorocrural PTFE bypass
with a distal vein cuff.
2. In combination with a prosthetic bypass the av-fistula increases the flow values both in
the intraoperative measurements and during immediate postoperative surveillance. This
increase in flow values does not, however, bring clinical benefit. Low intraoperative flow
and a poor papaverin response may predict poor graft patency. The reconstruction of an
adjuvant fistula caused marked adverse effects in only one patient, and after fistula closure
the symptoms resolved.
3. In a group of diabetic patients a radial forearm flap with an internal av-fistula markedly
increased the bypass graft flow. This method can be useful in selected cases with poor
run-off and large ischaemic lesions.
4. A free muscle flap connected to a vascular bypass graft functions as a large av-fistula,
circulating blood at a high velocity through the bypass graft. Consequently the distal
perfusion is improved.
5. The adjuvant av-fistula increases graft flow significantly in a poor outflow venous
bypass. Regardless of this, the av-fistula does not improve the outcome. This result is in
agreement with our results achieved with an av-fistula and a prosthetic graft.
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